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Abstract 
The ability of nutritional supplements to generate responses in productive animals at different 
physiological stages, and their interaction with the particular gastrointestinal tract of ruminants 
have created the necessity to explore effects beyond productivity. Modulation of immune function 
and inflammatory processes, modifications of nutrient metabolism, and interactions with the 
ruminal microbial population are effects attributed to supplements that encouraged the formulation 
of the set of experiments described in this dissertation. The first experiment was designed to test 
the effects of arachidonic and docosahexaenoic acids supplemented in milk replacer for Holstein 
calves during the pre-weaning period on the immune system, lipid and glucose metabolism, and 
growth performance when animals underwent a vaccination protocol.  Neither supplemental fatty 
acid source affected productivity, cytokine production, antibody production, or CD4 and CD8 cell 
proliferation. A treatment effect on glucose and NEFA plasma concentration was observed. 
Polyunsaturated fatty acids, mainly DHA, lowered glucose and NEFA levels compared to control; 
moreover, a dose effect was observed indicating that increasing amounts of PUFA decreased 
plasma glucose level. The second experiment tested the effects of Co carbonate (CoCarb) and Co 
glucoheptonate (CoGH) at different concentrations of Co on in vitro fermentation rate, 
fermentation end-products, and DM and NDF disappearance. Dry matter and NDF disappearance 
increased with CoGH relative to CoCarb at 1.0 ppm Co or less. CoCarb at > 3.0 ppm appeared to 
stimulate the biohydrogenation of long-chain fatty acids whereas CoGH had limited effects on this 
process.  Finally, the third study evaluated responses to chromium propionate during peak lactation 
and interactions between chromium and rumen-protected lysine and methionine. Chromium 
propionate increased feed intake and tended to increase energy-corrected milk yield. Primiparous 
cows showed greater responses in feed intake and milk protein yield than multiparous cows. In 
  
this study, feeding chromium propionate near peak lactation increased feed intake and tended to 
increase productivity but no benefits of supplementing rumen-protected lysine and methionine 
were observed. Overall, nutritional supplements helped to regulate different biological functions 
in ruminants; their utilization is not always is feasible, but the results of these experiments provide 
guidance about effectiveness during different physiological situations.   
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Abstract 
The ability of nutritional supplements to generate responses in productive animals at 
different physiological stages, and their interaction with the particular gastrointestinal tract of 
ruminants have created the necessity to explore effects beyond productivity. Modulation of 
immune function and inflammatory processes, modifications of nutrient metabolism, and 
interactions with the ruminal microbial population are effects attributed to supplements that 
encouraged the formulation of the set of experiments described in this dissertation. The first 
experiment was designed to test the effects of arachidonic and docosahexaenoic acids 
supplemented in milk replacer for Holstein calves during the pre-weaning period on the immune 
system, lipid and glucose metabolism, and growth performance when animals underwent a 
vaccination protocol.  Neither supplemental fatty acid source affected productivity, cytokine 
production, antibody production, or CD4 and CD8 cell proliferation. A treatment effect on 
glucose and NEFA plasma concentration was observed. Polyunsaturated fatty acids, mainly 
DHA, lowered glucose and NEFA levels compared to control; moreover, a dose effect was 
observed indicating that increasing amounts of PUFA decreased plasma glucose level. The 
second experiment tested the effects of Co carbonate (CoCarb) and Co glucoheptonate (CoGH) 
at different concentrations of Co on in vitro fermentation rate, fermentation end-products, and 
DM and NDF disappearance. Dry matter and NDF disappearance increased with CoGH relative 
to CoCarb at 1.0 ppm Co or less. CoCarb at > 3.0 ppm appeared to stimulate the 
biohydrogenation of long-chain fatty acids whereas CoGH had limited effects on this process.  
Finally, the third study evaluated responses to chromium propionate during peak lactation and 
interactions between chromium and rumen-protected lysine and methionine. Chromium 
propionate increased feed intake and tended to increase energy-corrected milk yield. Primiparous 
  
cows showed greater responses in feed intake and milk protein yield than multiparous cows. In 
this study, feeding chromium propionate near peak lactation increased feed intake and tended to 
increase productivity but no benefits of supplementing rumen-protected lysine and methionine 
were observed. Overall, nutritional supplements helped to regulate different biological functions 
in ruminants; their utilization is not always is feasible, but the results of these experiments 
provide guidance about effectiveness during different physiological situations.   
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Chapter 1 - Literature Review: Polyunsaturated Fatty Acids and its 
Role in Pre-Ruminant Diets 
 Introduction 
Historically, functions attributed to fatty acids had been mostly energy storage and 
substrate contributions to cellular membranes; however, through the years the increasing research 
on these molecules has demonstrated that fatty acids are able to play multiple roles, including the 
regulation of gene expression, modulation of lipid and glucose metabolism, modification of the 
activity of specific enzymes and membrane channels and signaling of potent molecules (Mashek 
and Grummer, 2003; Poirier et al., 2006). 
Despite the roles mentioned above, there is a limitation to the inclusion of lipids in rations 
for ruminants. The microbial population in the rumen does not have the ability to utilize the fatty 
acids. The presence of double bonds in the chain of the fatty acids represents a risk factor for some 
of the microbes, and they have to rearrange the lipid structures to reduce the degree of lipid toxicity 
and stabilize the ruminal environment (Maia et al., 2007; Zhang et al., 2008). This process is called 
biohydrogenation. Unfortunately, biohydrogenation restricts the amount of unsaturated fatty acids 
available for absorption in the small intestine, which limits the benefits of dietary polyunsaturates 
for the host animal. 
Methods to protect dietary lipids against microbial activity have been proposed and utilized 
((Palmquist et al., 1986; Jenkins and Bridges, 2007; Gadeyne et al., 2015), but their effectiveness 
is something that still is in debate and the outcomes have not been as expected when protected 
lipid are include in animals’ rations (Gadeyne et al., 2015).  
 2 
In the case of calves, their rumen is poorly developed in terms of size and functionality 
during the first days of life; the fermentative activity is very low because the microbial population 
has not fully colonized this organ yet. The rumen speeds its growth when solid feed is offered to 
the animal and the microbial population colonizes the foregut more intensively, but before this 
point, calves are functionally nonruminant. Nevertheless, the rapid rate of milk intake and the clot 
formation in the abomasum differentiates calves from true nonruminants (Bazin and Brisson, 
1976). 
Young ruminants have the esophageal groove that connects the esophagus with the 
abomasum (the biggest stomach section before weaning), and milk is delivered directly to this 
organ. This feature allows the calf to consume a large amount of lipids before weaning. In fact, 
when rations for newborns and weaned animals are compared, the proportion of lipids differs 
dramatically. Normally newborns consume greater amounts of this nutrient either from whole milk 
or milk replacer, whereas after weaning the proportion of fat decreases ((Hill et al., 2009a). 
This review will cover most of the important effects of lipids when they are included in 
rations for pre-weaning ruminants, and potential impacts of providing specific types and amounts 
of fatty acids. 
 
 Requirements for specific fatty acids for pre-ruminants 
A nutritional plan aims to impact animal performance by improving the precision of 
balancing ingredients and specific nutrients in rations. Also, the future performance of animals for 
milk production is related to how animals are fed during the early stages of life, and it has been 
observed that more milk is produced during the first lactation when animals were fed more 
intensively during the pre-weaning period (Drackley et al., 2007).  
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However, information on the effects and requirements of specific fatty acids in calves is 
scarce; as a result, fatty acid profiles have been ignored when rations for newborn calves are 
formulated (Jenkins et al., 1986; Hill et al., 2007). A study that compared whole milk to milk 
replacer, formulated to have the same fat and energy content, showed superior growth and feed 
efficiency in animals receiving whole milk (Bascom et al., 2007). These differences were partly 
attributed to the fact that whole milk contained more medium-chain fatty acids, whereas in milk 
replacer had more long chain fatty acids. Similar responses were observed when diets formulated 
with tallow, coconut oil and corn oil as sources of unsaturated and saturated fatty acids were fed 
to newborns. Medium chain FA are not stored and they are easily hydrolyzed in tissues, whereas 
long chain fatty acids are accumulated in fat deposits and metabolized when they are needed; 
actually, higher concentrations of linoleic acid in adipose tissue was detected with corn oil diets 
(Jenkins et al., 1985). 
The NRC (2001) has no estimates of requirements for fatty acids, but industry has enriched 
milk replacer with specific fatty acids and this practice has shown positive effects on growth and 
health status of young animals (Hill et al., 2009a; Garcia et al., 2014; Michalek et al., 2015). For 
example, the inclusion of increasing concentrations of linoleic acid in Holstein calf diets during 
the first 3 months helped to linearly increase average daily gain and feed efficiency, while also 
decreasing serum urea nitrogen and serum glucose concentrations (Hill et al., 2009a).  
Some intensified feeding programs focus on increasing skeletal growth (Cowles et al., 
2006), because by increasing the frame size it is possible to reduce the age at the first breeding 
(Heinrichs and Hargrove, 1987). Existing evidence associate PUFA to bone metabolism, 
suggesting that omega-3 fatty acids intervene in bone turnover (Kajarabille et al., 2013), a study 
measured alkaline phosphatase as indicators of bone formation (Watkins et al.,2001) observed how 
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increasing amounts of linoleic acid in the form of flax oil increased the concentrations of this 
parameter (Hill et al., 2009). When a commercial blend of butyric acid, coconut oil and flax seed 
oil was added to milk replacer and supplemented to Holstein calves (Hill et al., 2011), greater 
average daily gain was the outcome and the authors associated this effect with a possible increase 
in bone formation based on the greater concentrations of alkaline phosphatase. In addition, it was 
mentioned that the inclusion of butyrate in the blend could have a potential effect on pancreas 
development based on the increasing serum concentration of amylase observed in the groups of 
animals fed with the blend (Kato et al., 1989). Enriching milk replacer with coconut oil (replacing 
20 % of tallow) to increase the amount of medium chain fatty acids resulted in similar growth rates 
compared to whole milk when they were fed to Jersey calves for 49 days (Bowen Yoho et al., 
2013). 
More recently, Garcia et al., (2015) demonstrated that increasing the amount of essential 
fatty acids (cannot be synthesized by the organism) in calf diets can improve animal performance. 
Their results showed that feeding 0.0321 and 0.036 g/kg BW0.75 of linoleic acid and α-linolenic 
acid, respectively, during the first 60 d of life increased skeletal growth, observed as greater body 
weight gain and wither and hip heights. 
When animals receive more nutrients than what they need, the body must deal with the 
excess in some way (storage, metabolism, or excretion), but it is possible that overfeeding fatty 
acids could modify some metabolic functions by reducing the synthesis of other derivatives (Hill 
et al., 2011). For example, the synthesis of docohexaenoic acid from linolenic acid can be 
decreased if excessive amounts of linoleic acid are added to diets (Buccioni et al., 2012). One 
study supplied 1% of the dietary energy in the form of 18:2 n-6 and 18-3 n-3 fatty acids, and no 
treatment effects on performance of newborn calves were detected (Jenkins et al., 1986). A 
 5 
previous study  did not observe treatment effects on performance or immune cell response when 
neonatal lambs were fed milk replacer with oils rich in long chain n−3 or n−6 polyunsaturated 
fatty acids, although there were higher concentrations of total fatty acids and long chain fatty acids 
in plasma (Lewis et al., 2008). 
 
 Absorption of Fatty Acids 
The concentration of lipids in whole milk and milk replacers range from 17 to 28g/100g 
on a dry matter basis (Hill et al., 2009b; Bateman II et al., 2012). Most milk replacers utilize animal 
fats because they contain similar concentrations of saturated and unsaturated fatty acids compared 
to whole milk. On the other hand, milk replacer has a lower concentration of medium chain fatty 
acids and higher content of long chain fatty acids than whole milk, thus resulting in different rates 
of absorption and digestibility in the small intestine of young animals (Hocquette and Bauchart, 
1999).  
In pre-ruminants, milk or milk replacers barely enter the rumen, because the esophageal 
groove delivers the milk directly into the abomasum. As the major carbohydrate in milk (lactose) 
and the rest of the components reach the small intestine, lactose is enzymatically hydrolyzed when 
stimulates insulin secretion (Saltiel and Kahn, 2001). Insulin not only regulates the metabolism of 
glucose but also controls lipid metabolism (Dimitriadis et al., 2011). 
The formation of casein clots, catalyzed by renin and pepsin, limits the hydrolysis of fatty 
acids and delays the rate of absorption. Lipases can’t have immediate contact with triglycerides 
incorporated in these clots, so the fatty acids remain attached to the glycerol backbone for longer 
time (Hocquette and Bauchart, 1999; Okada et al., 2010)  
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The coagulate moves slowly to the small intestine where it gradually releases the nutrients. 
The total digestion of the clot lasts between 12 and 18 h (Bauchart et al., 1996), and the fatty acids 
become exposed to enzymatic action during that window of time. Now in the small intestine, the 
fatty acids are absorbed at different rates and by different routes based on the length of their 
aliphatic chain. The small intestine has less difficulty to absorb the medium chain fatty acids than 
long chain fatty acids; in fact, in human studies, these medium chain fatty acids have been used to 
enhance the permeability of mucosal tissues to hydrophilic drugs (Lindmark et al., 1998). To pass 
the brush membrane of the enterocytes, medium and long chain fatty acids combine with biliary 
bile acids, which have the ability to solubilize the fatty acids due to their amphiphilic surface. The 
mixtures of both components result in the formation of micelles (negatively charged spherical 
aggregates) that facilitate fatty acid absorption (Wang et al., 2013). The micelles do not enter the 
enterocyte; they create a kind of channel in the apical wall and allow the fatty acid to pass across 
an unstirred water barrier located in the intestinal microvillus membranes (Drackley, 2000).  
In addition to the micelle transport system, the presence of proteins on the surface of the 
enterocytes with roles as fatty acid transporters has been reported (Hayashi et al., 2013; Anderson 
and Stahl, 2013). These proteins directly interact with fatty acids and allow them to enter the 
enterocyte, possibly by simple diffusion (Wang et al., 2013). Some protein with this function, 
found in the intestinal cell membranes, are the fatty acid transport proteins (FATPs), fatty acid 
translocase (CD36), and fatty acid binding protein (FABP) (Bionaz et al., 2012; Kawano and 
Cohen, 2013; Tarhda and Ibrahimi, 2015). In the small intestine, two types of FABPs have been 
identified: the liver and intestinal-type FABPs (Poirier et al., 1996); however, the liver type 
particularly exhibits high binding affinity for two fatty acids, whereas the other proteins of the 
same family have affinity for just one fatty acid (Storch and Thumser, 2000).  
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 Metabolism of Essential Fatty Acids 
 Hydrolysis 
The chemical transformation of fatty acids in pre-ruminants begins when milk or milk 
replacer enters the mouth. Palatine glands and other tissues in the oral cavity secrete salivary 
lipases that hydrolyze mainly medium chain fatty acids from milk fat (Russell et al., 1980; Sun et 
al., 2002) ; only a small amount of long chain fatty acids can be separated from the triglycerides 
by this enzyme (Nelson et al., 1977). Despite the low effectiveness to release long chain fatty acids, 
the presence of pre-gastric esterase potentiates the action of other lipolytic enzymes present down 
the digestive tract (Edwards-Webb and Thompson, 1977; Sun et al., 2002). Previous studies 
observed how the concentration of triglycerides and phospholipids in plasma increased right after 
feeding, which indicates that these compounds were absorbed rapidly, and the action of the 
salivary enzymes could potentially contribute to this rapid hydrolysis and absorption (Bazin and 
Brisson, 1976). In addition, they observed that the concentration of NEFA and ketone bodies, 
mainly produced by the liver in pre-ruminants, did not show significant increases before feeding 
times, which could be due to the fact that the clot formation helped to maintain a more constant 
delivery of fatty acids between feeding times (Bazin and Brisson, 1976). 
During neonatal life, pre-gastric esterase is charged with the hydrolysis of triaglycerides, 
until the pancreatic lipase increases its activity (Russell et al., 1980). 
Pancreatic lipases continue the hydrolysis of fatty acids from triacylglycerides. This 
enzyme specifically attacks the fatty acids located in sn-1 and sn-3 positions, releasing 2 fatty acids 
and a monoacylglyceride (glycerol + fatty acid in sn-2 position). During the postnatal period, the 
enzyme activity increases 1.6 to 2.2 fold (Le Huerou-Luron et al., 1992), but it also requires the 
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presence of colipase, a cofactor that helps the enzyme to localize at the lipid-water surface and 
prevents the wash off of the enzyme by the bile salts (Parker et al., 2014).  
 
 Reassembly of Triglycerides 
The re-esterification of triglycerides in mammals can occur by 2 different pathways. In 
most cells the process occurs predominantly by the glycerol-3-phosphate (G3P) pathway; 
however, the enterocytes are the exception and inside these cells, the re-assembly of triglycerides 
takes place by the action of 2 enzymes: monoacylglycerolacyltransferase (MAGT) and 
diacylglyceroltransferase (DGAT) (Alves-Bezerra and Gondim, 2012). 
 
 Chylomicron Formation and Transport 
Now inside the intestinal cell, the re-formed dietary triglycerides are incorporated into 
chylomicrons that carry them out of the cell and distribute them to other tissues. The chylomicrons 
have a globular micelle-like structure with an internal core of non-polar hydrophobic molecules 
(triglycerides and cholesteryl esters), and the external shell composed of cholesterol, phospholipids 
and apolipoproteins (Randolph and Miller, 2014). Several apolipoproteins are present on the 
surface of chylomicrons such as apo-B48, apo-A1 and apo-AIV, but among them, apo-AIV 
participates more in the metabolism of lipids. For example, it participates in reverse cholesterol 
transport, modulates lipoprotein lipase activity, and moderates the interactions between different 
lipoproteins (Michalek et al., 2015). During the neonatal period when calves consume large 
amount of fat from milk, the expression of apo-AIV significantly increases due to the increase of 
lipid absorption in the small intestine (Sahl et al., 2003). 
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Once embedded in the chylomicrons, the triglycerides are transported from the lumen to 
intestinal lymph ducts or via the portal vein (Hocquette and Bauchart, 1999; Wang et al., 2013). 
The chylomicrons in the blood stream won’t last for long because they enter into contact with the 
enzyme lipoprotein lipase (Mead et al., 2002). This enzyme is present in most tissues, especially 
adipose, muscle and heart; it plays an important role in the clearance of triglycerides from the 
blood stream. Lipoprotein lipase utilizes the presence of apoliproteins on the surface of 
chylomicrons to recognize and initiate the hydrolysis of the triglycerides. The free fatty acids can 
then be absorbed mainly by diffusion in most tissues, but also go to the liver as glycerol does.  
 
 Fatty Acid β-oxidation 
The high pumping activity of heart demands large amounts of energy, obtained mainly 
from fatty acids. Heart under normal conditions utilizes very efficient fatty acid β-oxidation 
machinery to get energy (Grynberg and Demaison, 1996); but during challenging situations, it can 
switch to alternative and faster ATP-producing pathways (Sack et al., 1996; Lopaschuk et al., 
2010). In the case of muscle tissue, contraction frequency and intensity dictates when and from 
where to get energy (glucose, ketone bodies and fatty acids); but muscle tissue also gets fuel from 
fatty acids by using the β-oxidation pathway (Fryan et al., 2006).  
The b-oxidation pathway is a multiple phase process used by most tissues to obtain fuel 
from medium and long chain fatty acids (Li et al., 2012). It requires an initial activation step that 
occurs in the cytoplasm (Kunau et al., 1995). The enzyme acyl-CoA synthetase, in an ATP-
dependent reaction, removes two inorganic phosphates and adds the coenzyme-A to the end the 
fatty acid, generating the activated fatty-acyl-CoA (Suzuki et al., 1990). Once the fatty acid is 
activated, the acyl-CoA needs to enter the mitochondria for the oxidative process. Carnitine 
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palmitoyl transferase-I attaches carnitine to the acyl-CoA and transports the fatty acid into the 
mitochondria (Holloway et al., 2006). Inside the organelle, a second enzyme called carnitine 
palmitoyl transferase-II detaches the fatty acyl-CoA, and returns the carnitine to the cytoplasm 
(Djouadi et al., 2003; Bartlett and Eaton, 2004). Now the fatty acid initiates the oxidative pathway, 
where the fatty acyl-CoA dehydrogenase removes 2 hydrogens and generates a double bond on 
the fatty acid chain. The end products of this reaction are trans-D2-enoyl-CoA and FADH2, which 
is equivalent to 1.5 ATP (Kurtz et al., 1998; Lopaschuk et al., 2010).  
In the following step, the enzyme trans-D2-enoyl-CoA hydratase hydrates the double bond 
by adding an OH- group to the carbon in position 3 and a H+ to carbon in position 2; the resulting 
molecule is 3-L-hydroxyacyl-CoA (Guzmán and Geelen, 1993; Agnihotri and Liu, 2003).  
One H+ and one H- are removed from 3-L-hydroxyacyl-CoA, and b-ketoacyl-CoA (with 
two keto-groups) is generated in a reaction where 3-L-hydroxyacyl-CoA dehydrogenase also 
produce 1 molecule of NADH, which yields 2.5 ATP (Schulz et al., 2011) The final step is the 
Claisen ester cleavage, where the action of the enzyme b-ketoacyl-CoA thiolase inserts another 
CoA molecule to separate the b-ketoacyl-CoA into two molecules, acetyl-CoA and a fatty acyl-
CoA. This last molecule is a fatty acid chain 2 carbons shorter than the fatty acid that initiated the 
process (Kantor et al., 2000; Reddy and Rao, 2006). The whole oxidative process continues until 
no more cleavage can be done. On the other hand, the acetyl-CoA is moved to the citric acid cycle 
to generate additional energy.  
 
 Polyunsaturated Fatty Acid β-oxidation 
The process for unsaturated and polyunsaturated fatty acids requires extra steps to remove 
the double bonds. The β-oxidation process occurs as it was described until a double bond is found. 
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In monounsaturated fatty acids, the double bond is typically located at an odd carbon. Since the 
cleavage steps cut two carbons at a time, the double bond will end in the 3rd carbon, so it requires 
isomerization that moves the double bond to the carbon in 2nd position. The enzyme charged with 
this task is called cis-D3-enoyl CoA isomerase (Mursula et al., 2001). The action of this enzyme 
does not requires extra energy; however, the unsaturation of a fatty acid has an energetic cost 
because the addition of the double bond by fatty acyl-CoA dehydrogenase is not required and no 
FADH is produced in this step, so less energy is generated when an unsaturated fatty acid is placed 
in the mitochondria for oxidation. When more than one double bond is in the fatty acid, besides 
the isomerase, another enzyme is involved in the process. Usually the bonds are 3 carbons apart, 
and after the isomerase acts on the first double bond and the cleavage happens, the following bond 
could be in even position. The fatty acyl-CoA dehydrogenase introduces a double bond and 2,4-
dienoyl CoA is generated (Fillgrove and Anderson, 2001), which is an unusual structure that must 
be modified. Therefore, the 2,4-dienoyl CoA reductase consumes 1 NADH2 to reduce one of the 
double bonds, and then the cis-D3-enoyl CoA isomerase does its job (Alphey et al., 2005). 
Polyunsaturated fatty acids therefore generate less energy than saturated acids of the same chain 
length.  
 b-oxidation takes place not only in the mitochondria; peroxisomes can also execute this 
function (Cherkaoui-Malki et al., 2012). In this organelle, the process only incompletely oxidizes 
long and very long chain fatty acids to medium chain fatty acids (Reddy and Hashimoto, 2001). 
Afterwards, the resulting molecules move to the mitochondria for further oxidation. The first 
enzyme participating in the peroxisomal b-oxidation is the fatty acyl-CoA oxidase, which produces 
trans-D2-enoyl CoA and water. Then, enzymes similar to those in the mitochondria perform the 
hydration and oxidation. The final step is executed by the peroxisomal thiolase, which, in contrast 
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to the thiolase in the mitochondria, stops when the cleavage reaches an acyl-CoA with less than 8 
carbons (Mannaerts et al., 2000). 
 
 Lipid Metabolism in the Liver 
Liver plays a pivotal role in uptake, circulation and synthesis of fatty acids; several 
metabolic pathways, regulated by dietary lipids and hormones, have been characterized 
(Hocquette and Bauchart, 1999). As in other tissues, liver recognizes chylomicrons and VLDL 
through the apolipoproteins located on the surface of these structures. Uptake of medium and 
long chain fatty acids in this organ also requires their activation by the action of either acyl-CoA-
synthetase or fatty acid binding protein (FABP) (Nguyen et al., 2008). Previous work 
demonstrated how the transcriptional expression of FABP in monogastrics increased when long 
chain fatty acids were supplemented in the diet (Meunier-Durmort et al., 1996), which could be 
significant for pre-weaned calves despite the fact that this mechanistic approach has not been 
proven in ruminants. Once they are activated, fatty acids follow a similar mechanism to enter 
either the mitochondria or peroxisomes for oxidation, or will go into the nucleus to interact with 
some transcription factors (Rui, 2014).  
 
 Ketone Bodies Production 
In addition to b-oxidation, ketone bodies (acetoacetate, BHBA and acetone) can be 
produced in the liver to be used as energy currency to provide metabolic fuel to other tissues when 
the animal is on fasting and blood glucose levels decrease (Rui, 2014). This process is activated 
when the uptake of fatty acid is high and the concentration of chylomicrons and VLDL increase 
in the blood stream. Ketogenesis begins with 2 molecules of acetyl-CoA combined by the action 
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of a thiolase enzyme to produce acetoacetyl-CoA, the hydromethylglutaryl-CoA-synthase to add 
another acetyl-CoA, and the hydroxymethylglutaryl-CoA lyase to cut the resulting molecule in 
two pieces to finally produce acetoacetate (McGarry and Foster, 1980). From here, BHBA and 
acetone are generated, the first through the action of β-hydroxybutyrate dehydrogenase, and the 
second one by a non-enzymatic decarboxylation (Enjalbert et al., 2001). 
 
 Synthesis of Long Chain Fatty Acids 
Importantly, in non-ruminants the liver is the major site for the formation of fatty acids, 
whereas in ruminants, adipose tissue does this labor (Pethick and Dunshea, 1996).  
 
 Tricarboxylate Transport System 
The hepatic synthesis of fatty acids is considered the reverse of β-oxidation, and it requires 
acetyl-CoA produced in the mitochondria. But this molecule must be transported out to the cytosol, 
where the formation of the fatty acids takes place, and this action is performed by the tricarboxylate 
transport system (Bisaccia et al., 1989). This system involves 3 enzymes located in the cytosol, 
ATP-citrate lyase, malate dehydrogenase, and malic enzyme, and another enzyme found inside the 
mitochondria, pyruvate carboxylase (Minarik et al., 2002; Pongratz et al., 2007). The acetyl-CoA 
cannot cross the membrane by itself, so it is converted to citrate when combines with oxaloacetate 
in a reaction catalyze by citrate synthase. The citrate is pumped out, and once in the cytosol the 
ATP-citrate lyase detaches acetyl-CoA and oxaloacetate at the expense of 1 ATP. Malate 
dehydrogenase and malic enzyme reconvert the oxaloacetate to pyruvate, and this molecule is 
transported back into mitochondria where pyruvate carboxylase generates oxaloacetate back to 
start the cycle again (Attwood, 1995).  
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 Fatty Acid Synthesis 
Outside the mitochondria, acetyl-CoA carboxylase, which contains biotin, produces 
malonyl-CoA when it adds CO2 to acetyl-CoA (Abu-Elheiga et al., 2001). The next step is 
catalyzed by fatty acid synthase; this single polypeptide chain is equipped with multiple functional 
sites (enzymatic roles) and an acyl-Carrier-Protein (ACP). In fact, 7 reactions occur in this protein 
to complete the formation of the fatty acids (von Wettstein-Knowles et al., 2006).  
The malonyl CoA is anchored to the ACP by the action of the malonyl/acetyl-CoA-ACP- 
transacylase (MAT), releasing the CoA group and producing malonyl-ACP. This compound is the 
activated donor of 2 carbons and another molecule of acetyl-CoA is the receiver after being 
converted to acetyl-ACP by MAT in another similar enzymatic complex (Smith, 1994; Berg JM, 
Tymoczko JL, Stryer L, 2002). 
The elongation reaction is triggered by decarboxylation of acetyl-ACP, the enzyme b-
ketoacyl-ACP-synthase begins the construction of the fatty acyl chains by joining the malonyl-
CoA with acetyl-ACP, and the resulting molecule is the 4-carbon acetoacetyl-ACP (Christensen 
et al., 2007). Then 3 enzymes, 2 reductases (b-ketoacyl-ACP-reductase and enoyl-ACP-reductase) 
and 1 dehydrogenase (b-hydroxyacyl-ACP-dehydrase) act alternately to catalyze the conversion 
to an alkyl group; this portion of the pathways repeats up to 7 times to add 2 C per cycle (von 
Wettstein-Knowles et al., 2006). The final product, palmitoyl-ACP, is then transformed to 
palmitate when a thioesterase enzyme cleaves the ACP (Svensson et al., 1995).  
The main product of lipogenesis in animals is palmitate, but further elongation can be 
performed by different elongases present in adipose tissue, mainly to generate stearic acid. 
Additionallly, D-9-desaturases catalyze the reaction through which is possible to introduce double 
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bonds, converting palmitic acid to palmitoleic acid and stearic acid to oleic acid (Engler et al., 
2000). Interestingly, in a study performed with rats, when animals were fed high fat diets, 
lipogenesis in liver was induced to elongate and desaturase the fatty acid rather than to increase de 
novo synthesis (Oosterveer et al., 2009) consistent with the previous statements which indicated 
that intracellular concentration of fatty acid synthase decreased in high fat diets (Hillgartner et al., 
1995).  
 
 Omega-3 and Omega-6 Fatty Acids 
Polyunsaturated fatty acids with double bonds close to the methyl end have gained a lot of 
attention in the last decades since an epidemiologic study demonstrated that the Eskimo population 
in Greenland showed low incidence of type-1 diabetes and other autoimmune and inflammatory 
disorders (Kromann and Green, 1980), attributed to the daily intake of fish with large content of 
omega-3 fatty acids. 
The omega classification refers to the position of the first double bound, so omega-3s have 
their first double bond on carbon 3 from the methyl end, and omega-6 on carbon 6 (DeFrain et al., 
2005; DeFilippis and Sperling, 2006). The presence of a double bond and the carbon where they 
are positioned mark significant differences in the physiological responses attributed to these fatty 
acids.  
Some of the most important PUFA are: arachidonic acid (C20:4, n-6), a-linoleic acid 
(C18:2, n-6), a-linolenic acid (C18:3, n-3) eicosapentaenoic acid (C20:5, n-3) and 
docosahexaenoic acid (C22:6, n-3) (Schmidt and Dyerberg, 1994). The lack of mechanism to 
endogenously synthesize these compounds forces mammals to obtain them from dietary sources. 
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The omega-6 and a-linolenic acid can be found in meat, cereals, nuts and seeds; the other group 
is highly present in fish and seafood (Meyer et al., 2003).  
Benefits for health have been attributed more to omega-3 than to omega-6 fatty acids. 
Eicosanoids are bioactive molecules derived from these fatty acid families (DeFilippis and 
Sperling, 2006); however, the position of the double bond results in a different mode of action at 
the cellular level.  The omega-6 family has been linked to pro-inflammatory responses 
(Simopoulos, 2008), whereas omega-3 fatty acids are associated with anti-inflammatory roles 
(Kitessa et al., 2004) .  
 
 Omega-3 Fatty acids and Inflammation 
 Prostaglandin Metabolism  
The formation of prostaglandins from omega-3 fatty acids is mediated by the action of 
cyclooxygenase and lipoxygenase enzymes. When arachidonic acid is release from plasma 
membranes by phospholipases, cyclooxygenases (COX-1 and -2) convert it to prostaglandin (PG) 
H2, and the action of a series of specific isomerases produces 4 types of bioactive prostaglandins 
and thromboxanes. The activity of COX-2 couples more with the production of prostacyclin PGI2, 
thromboxane (TX) A2 and PGE2 (Ricciotti and FitzGerald, 2011). On the other hand, lipoxygenase 
converts arachidonic acid to 5-HPETE (5-hydroperoxyeicosatetranoic acid); through a reaction 
catalyzed by LTA synthase, 5-HPETE is converted to leukotriene-B4 or leukotriene-C4, which is 
rapidly metabolized to leukotriene D4 (O'Donnell, 1999).  
Prostaglandine E2 is produced during inflammation, influences dendritic cell and T-helper 
cell differentiation, and increases vascular permeability and sensitivity to pain (Chizzolini and 
Brembilla, 2009). Thromboxane A2 is a potent platelet aggregator and vasoconstrictor, and 
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leukotriene-B4 induces inflammation and leukocyte chemotaxis and adherence (Simopoulos, 
2008).  
When omega-3 fatty acids are included in the diet, these compounds compete with omega-
6 fatty acids in the formation of phospholipids. Omega-6 fatty acids are most often placed in the 
n-2 position of phospholipids, but omega-3 fatty acids also use the same enzymes and position, so 
they are able to replace the majority of omega-6 fatty acids in the cell membrane. When 
phospholipases disassemble the phospholipids, a switch in the formation of prostaglandins occurs. 
Eicosapentaenoic acid is metabolized via the same pathway as arachidonic acid, but different end-
products and different effects on the cellular function are triggered depending on the substrate 
entering the pathway. The cyclooxygenase produces PGE3 from EPA instead of PGE2 (Bagga et 
al., 2003), and this prostaglandin is believed to lessen the degree of inflammation; however, recent 
studies observed that both PGE3 and PGE2 increased paracellular permeability (Roche et al., 2005; 
Rodríguez-Lagunas et al., 2013). Omega-3 fatty acids increase the production of the platelet 
aggregator and vasoconstrictor thromboxane A3, but these effects occur to a lesser degree 
compared to those produce by TXA2. The LTA-synthase, using EPA as a substrate, produces a 
weaker inducer of inflammation and weak chemotactic leukotriene (LTB5).  
 
 Cytokine Production 
Eicosapentaenoic and docosahexaenoic acid have been proven to inhibit the production of 
pro-inflammatory cytokines, and the activation of peroxisome proliferator-activated receptor 
(PPAR) is one of the mechanism proposed. An experiment that examined if EPA or DHA generate 
anti-inflammatory responses by acting on these receptors observed that both fatty acids activated 
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PPAR-g and reduced the concentration of lipopolysaccharides in human renal tubular cells by 
inhibiting the activation of nuclear factor NF-kB (Li et al., 2005).  
Previous evaluations done (Mishra et al., 2004) in human umbilical vein endothelial cells 
showed that oxidized EPA potently decreased TNFα and IL-1ß production induced by monocyte 
chemoattractant protein 1 (MCP-1), but the omega-3 fatty acid had a lesser effect following IL-8 
stimulation (Mishra et al., 2004). Another group (Serini et al., 2012) observed that the addition of 
purified DHA or EPA effectively reduced cytokine release by phytohaemagglutinin-stimulated 
peripheral blood mononuclear cells in vitro, and the effect was more prominent with DHA on these 
cells obtained from patients with Alzheimer disease. A previous study mentioned that these 
omega-3 fatty acids, besides causing a reduction of TNFα release, also decreased the production 
of IL-10 and INF-g (Verlengia et al., 2004).   They documented that the mechanism of action for 
these polyunsaturated fatty acids is through changes in the expression of genes clustered to 
cytokine production, signal transduction, transcription, cell cycle control, defense and repair, 
apoptosis, cell adhesion, cytoskeleton, and hormones. 
 
 Resolution of Inflammation 
The first objective of the inflammatory process is to neutralize pathogenic invaders and 
then to initiate the repair of the damaged tissue (Maskrey et al., 2011). During acute inflammation, 
neutrophils initiate the defense against pathogens, and at the same time the lipid-derived pro-
inflammatory prostaglandins and leukotrienes are produced. Then mononuclear cells and 
macrophages are recruited to clean the house and finally return the tissue to homeostasis. However, 
restoring to the homeostatic state does not occurs after inflammation is controlled; existing 
evidence proved that events such as activation of phagocytosis, apoptosis, and release and 
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clearance of cytokines and chemokines occur at the onset of acute inflammation (Buckley et al., 
2014). This mechanism is attributed to lipid-derived substances known as specialized proresolving 
mediators (SPM), and these molecules have the ability to control the acute inflammation in terms 
of duration and the magnitude. Additionally, proresolvins also control the return to homeostasis 
during the decline of the disease, because they are biosynthesized right after the pro-inflammatory 
factors are secreted (Serhan, 2010).  
Despite being anti-inflammatory, the proresolution process has significant mechanistic 
differences from inhibitors of inflammation. SPMs do not reduce prostaglandins or leukotrienes 
biosynthesis or inhibit enzymatic pathways as was observed in a study with transgenic mice that 
endogenously synthesized omega-3 from omega-6 (Hudert et al., 2006).  These molecules 
stimulate the clearance of cytokines and chemokines by macrophages, stop the recruitment and 
infiltration of neutrophils, and also regulate the removal of apoptotic neutrophils and cellular waste 
(Serhan, 2010; Spite et al., 2014). 
Precursors of SPM are mainly essential fatty acids in the omega-6 and omega-3 families. 
A group called lipoxins is derived from arachidonic acid in a process that involves the action of 5- 
and 15-lipoxygenases(Samuelsson et al., 1987). Another set of SPM denoted as resolvins is 
produced from EPA through different enzymatic mechanisms (Ogawa and Kobayashi, 2009; 
Allard et al., 2011; Rodriguez and Spur, 2012), but also can be synthesized when aspirin is present 
in a reaction that involves cyclooxygenase-2 (Serhan, 2010; Freire et al., 2011). Protectins and 
maresins come from DHA; protectins are synthesized by a lipoxygenase-dependent reaction 
(Serhan et al., 2015), whereas maresin formation requires a series of enzymatic reactions where 
DHA is hydroperoxidated, epoxidated and finally hydrolyzed (Sasaki et al., 2011).  
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The proresolvin approach provides a better understanding about how omega-3 fatty acids 
participate in the regulation of inflammation processes.  For example, a previous report mentioned 
that resolvin-E1 interacted with the receptor ChemR23 to attenuate nuclear factor–kB mediated 
inflammation (Arita et al., 2005), and another group of researchers observed a reduction of 
inflammatory status in transgenic mice producing higher endogenous levels of n-3 FA, suggesting 
that omega-3 FA have a wide range of effects on molecular function in resolution of inflammation 
and organ protection (Hudert et al., 2006). 
 
 Omega 3 Fatty Acids and Energy Homeostasis 
 Glucose Metabolism and Lipid Metabolism 
The contribution of omega-3 fatty acids in glucose metabolism has been evaluated in a 
wide range of experiments from clinical to cell culture models. Among the effects, improvements 
in insulin sensitivity in muscle tissue have been associated with the inclusion of unsaturated fatty 
acids in cell membranes (de Santa Olalla et al., 2009). A previous research observed a significant 
reduction in glucose and insulin concentrations, suggesting an increase in insulin sensitivity, when 
providing 1200 mg of omega-3 fatty acids to women with polycystic ovary syndrome and high 
risk of type 2 diabetes (Rafraf et al., 2012). However, previous studies observed adverse effects in 
glucose metabolism when fish oil was supplemented in rats (Borkman et al., 1989) and humans 
(Glauber et al., 1988). Despite the previous reports, a more recent study noted that the omega-3 
index, measured as the concentration of EPA and DHA in red blood cells, was positively correlated 
with insulin sensitivity in overweight men (Albert et al., 2014).  
Two different type of mice (wild type and GPR120 knockout) were used in an experiment 
to address the mechanistic effects of EPA and DHA on insulin sensitivity (Talukdar et al., 2010)  
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G- protein-couple receptors respond to fatty acids and are highly expressed in adipose tissue. After 
both groups consumed diets promoting obesity and insulin resistance, the supply of the omega-3 
fatty acids enhanced insulin sensitivity and reduced inflammation in the wild type animals, but the 
mice without the receptor failed to respond in the same manner.  
Omega-3 fatty acids have also been associated with modulation of lipid metabolism and 
lipoprotein concentration (Simopoulus, 1991); these compounds are associated with reduced risk 
of cardiovascular diseases in humans due to their ability to decrease platelet aggregation and blood 
viscosity by decreasing plasma concentration of low density lipoproteins (LDL) and very low 
density lipoproteins (VLDL) (Illingworth et al., 1984). 
A research reported the effects of DHA and EPA on glucose and lipid metabolism in bovine 
hepatocytes in vitro, and they found that DHA modulated the metabolism of palmitic acid toward 
the formation of triglycerides, phospholipids and cholesterol (Mashek et al., 2002). But in a follow 
up study, using radiolabeling techniques it was discovered that DHA regulates enzymes involved 
in the triglycerides synthesis, and suggested a more feasible effect over enzymes involved in the 
esterification of free fatty acids to triglycerides such as diacylglycerol acyltransferase (Mashek and 
Grummer, 2003).  
 
 Conclusion 
Polyunsaturated fatty acids are versatile compounds with effects on a wide range of biological 
functions. Their different modes of action, even in animals of the same species but at different 
physiological age, establishes the necessity to dig more into the potential of these molecules. The 
impact of fatty acids on metabolic diseases and immune function gives a bonus to their 
supplementation in diets for livestock, not only as a source of energy but also as modifier of health.  
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 Abstract 
Polyunsaturated FA have been linked with modulatory effects in a wide range of biological 
functions. The objectives for this study were: 1) to determine if docosahexaenoic (DHA) or 
arachidonic acid (ARA) affect pre-weaning glucose and lipid metabolism, and 2) to determine if 
increasing concentrations of both FA in milk replacer modulates the immune response to 
vaccination. Thirty Holstein newborn calves with birth weights between 31 and 45 kg were 
blocked by date of birth and, within block, randomly assigned to 1 of 5 treatments. Treatments 
were control (choice white grease), low dose of ARA (1.6 g/d), high dose of ARA (4.8 g/d), low 
dose of DHA (1.6 g/d) and high dose of DHA (4.8 g/d). All treatments provided a total of 1% 
added lipid (DM basis), with choice white grease added to ARA and DHA treatments to equalize 
fat content. Growth parameters, lipid and glucose metabolites, inflammation mediators (TNFα and 
haptoglobin), antibody titers for BRSV, BVD1 and -2, and peripheral blood mononuclear cell 
proliferation after vaccination were the variables measured. Data were analyzed with mixed 
models including the fixed effects of treatment, time, and their interaction, and the random effect 
block and of heifer within block. Contrasts were used to evaluate effects of fatty acid source and 
total essential fatty acid (EFA) supply. Dry matter intake, ADG and feed efficiency were not 
affected by treatments. Docosahexaenoic acid increased height at the withers relative to ARA (P 
< 0.05) but increasing EFA supply slowed the growth in pin-bone width (P < 0.05). Glucose 
concentration increased when the dose of PUFA increased (P < 0.05). Plasma β-hydroxybutyrate 
and triglyceride concentrations were not affected by treatment. Inflammatory markers, antibody 
titers, CD4 cells and CD8 cells were not different between treatments (P>0.10). The 
supplementation of DHA and ARA modulated glucose and lipid metabolism but had few effects 
on performance and immune response to vaccination in pre-weaning calves. 
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 Introduction 
Nutrient intake during the pre-weaning period affects the partitioning of nutrients among 
different tissues and their biological activities. Several studies have demonstrated how the 
improper balance of nutrients greatly affects ADG, skeletal growth and lean muscle mass of 
growing calves (Cowles et al., 2006; Swank et al., 2013; Garcia et al., 2015). Nevertheless, the 
fact that newborns have the esophageal groove, allows them to utilize alternative dietary sources 
whose potential is limited when the rumen is fully functional. One example is the inclusion of fat 
in milk replacer to increase dietary energy density. Furthermore, it is possible to deliver specific 
fatty acids (FA), which have been identified as modulators of different metabolic pathways 
(Dänicke et al., 2012; Swank et al., 2013).  
Long chain FA (C22:6 specifically), tested in monolayer cultures of bovine hepatocytes, 
affected both glucose and lipid metabolism (Mashek and Grummer, 2003). An in vivo study of 
essential fatty acid supplementation for calves showed greater concentrations of circulating β-
hydroxybutyrate when feeding milk replacer enriched with medium-chain FA in place of linoleic 
acid (Garcia et al., 2015). In addition, the expression of genes related to lipid metabolism increased 
when LCFA 20:5(n-3), 16:0 and 18:0 were added to Madin–Darby Bovine kidney cell culture 
(Bionaz et al., 2012). 
Among the essential FA, special emphasis has been placed on omega-3 FA during the last 
decades, and multiple species have been the target of investigation. In human diets, the omega-3 
FA have been evaluated for treatment of hyperlipidemia, hypertension, and rheumatoid arthritis 
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(Covington, 2004). The low prevalence of metabolic syndrome and type-2 diabetes in Eskimo 
populations in Alaska may be related to high consumption of this class of FA (Ebbesson et al., 
2005). In horses, it was observed that the supplementation of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) influenced the profile of circulating FA (King et al., 2008). In rats, 
when as little as 6% of dietary linoleic acid was replaced with omega-3 FA (FA) from fish oil, the 
development of insulin resistance was prevented (Storlien et al., 1987). Arachidonic acid (ARA) 
with its first double bond placed in carbon 6, is another key component of cell membranes and a 
precursor of chemical mediators (prostaglandins, leukotrienes, and lipoxins) attributed with 
important actions on inflammation an resolution (Buckley et al., 2014); the responses linked to the 
omega-6 FA family are pro-inflammatory (Simopoulos, 2002).  
Beyond their influence on metabolic activities, omega-3 FA also have been investigated 
for their capacity to modulate immune cell function and inflammatory responses (Greco et al., 
2015). It has been reported that DHA and EPA in mice induced potent anti-inflammatory responses 
through their effect on G-protein receptor 120 (Talukdar et al., 2010), which is expressed primarily 
in adipose tissue and pro-inflammatory macrophages. In piglets during the weaning period, 
animals fed with 3% marine omega-3 FA had lower plasma concentration of TNFα, a response 
associated with a reduction of stress caused by the weaning process (Li et al., 2014). In study done 
with Holstein calves, omega-3 FA tended to decrease gene expression of TNFα in LPS-stimulated 
cells when fish oil was the source; when flax oil was used, the expression of IL-4 was decreased, 
(Karcher et al., 2014). This indicated the potential of the FA to regulate cytokine gene expression. 
Docosahexaenoic acid has specific effects on immune function and inflammatory 
processes, and these are not necessarily linked to EPA as its precursor.  An experiment that 
examined if EPA or DHA generate anti-inflammatory responses observed that both fatty acids 
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activated PPAR-g and reduced the concentration of lipopolysaccharide in human renal tubular cells 
by inhibiting the activation of nuclear factor NF-kB (Li et al., 2005). Another group (Serini et al., 
2012) observed that the addition of purified DHA or EPA effectively reduced cytokine release by 
phytohaemagglutinin-stimulated peripheral blood mononuclear cells in vitro, and the effect was 
more prominent with DHA.  
Moreover, protectins and maresins, molecules that stimulate the clearance of cytokines and 
chemokines by macrophages, stop the recruitment and infiltration of neutrophils, and also regulate 
the removal of apoptotic neutrophils and cellular waste (Serhan, 2010; Spite et al., 2014), come 
from DHA; protectins are synthesized by a lipoxygenase-dependent reaction (Serhan et al., 2015), 
whereas maresin formation requires a series of enzymatic reactions where DHA is 
hydroperoxidated, epoxidated and finally hydrolyzed (Sasaki et al., 2011). 
In this experiment, we aimed to determine if docosahexaenoic (DHA) or arachidonic acid 
(ARA) affected pre-weaning glucose and lipid metabolism. In addition, we sought to determine if 
increasing concentrations of DHA or ARA in milk replacer, using relatively purified sources, could 
modulate the immune function of calves when they undergo a vaccination protocol. 
 
 Materials and Methods 
All protocols were approved by the Kansas State University Institutional Animal Care and 
Use Committee. 
 
 Animals and Management 
Thirty Holstein heifers were enrolled within 12 h of birth. The dams gave birth in an open, 
cooled barn, and newborns were immediately removed from their side and their body weight was 
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recorded. Within the first hour of life, 1.42 L of colostrum was offered to the calves; the calves 
consumed almost all the colostrum offered, so drenching was not necessary. Five h later a second 
dose of colostrum (1.42 to 1.89 L) was offered to the newborns, and a third dose of similar amount 
was offered 6 h later. The aim was to supply 5.67 L of colostrum within 12 h of birth. The 
colostrum was collected previously and evaluated with a brix refractometer to determine total 
solids as an indirect measure of IgG concentration (Quigley et al., 2013). If colostrum had a brix 
value greater than 22%, the cut-off value for high IgG concentration (Bielmann et al., 2010; 
Chavatte et al., 1998), it was stored at -4°C, and when needed it was thawed in a water bath at 
20°C. After the last colostrum feeding (about 12 h after birth), the calves were moved out of the 
maternity barn into individual hutches bedded with straw, where they remained until the end of 
the study.  
The exclusion criteria for enrollment were: dystocia at birth (calving difficulty score ≥ 3), 
twins, and birth weight < 31 kg or > 45 kg. Enrolled calves were blocked by date of birth, and 
within block they were randomly assigned to 1 of 5 treatments (n = 6 animals per treatment). The 
treatments consisted of the addition of 1.0% extra fat to the basal milk replacer with the following 
composition: 
1. Choice white grease (CWG) 
2. CWG + low dose ARA (ARA = 1.6 g/d or ~ 100 mg/kg BW0.75) 
3. CWG + high dose ARA (ARA = 4.8 g/d or ~ 300 mg/kg BW0.75) 
4. CWG + low dose DHA (DHA = 1.6 g/d or ~ 100 mg/kg BW0.75) 
5. CWG + high dose DHA (DHA = 4.8 g/d or ~ 300 mg/kg BW0.75) 
The primary difference between treatments was the concentration of DHA and ARA. Two 
different oils were utilized as sources of extra fat: a fungal oil with a concentration of 40% ARA 
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(ARASCO, DSM Nutritional Products, Basel, Switzerland) and an algal oil with 40% of DHA 
(DHASCO, DSM Nutritional Products). Fatty acid content, energy and protein concentrations 
among treatments remained similar.  
Color-coded treatment supplements containing the appropriate dose of each oil for 1 
feeding were prepared in the Ruminant Nutrition Laboratory at Kansas State University; 
technicians in charge of feeding at the KSU dairy unit were blinded to the treatments.  
At each feeding time (0000, 0800 and 1600 h), 0.27 kg of milk-replacer powder (Cow’s 
Match, Land O’Lakes Animal Milk Products Co., Shoreview, MN) containing 27.59% CP, 19.85% 
fat, and 4.98 Mcal GE/kg DM, was weighed, mixed with 1.0 L of hot water (49°C) and put in the 
bottles. Pre-weighed treatment mixtures were then immediately poured into the bottles, in the 
following proportions: 3.0 g of CWG for the control treatment, 1.33 g of ARASCO + 2.41 g of 
CWG for low dose of ARA, 4.0 g of ARASCO + 1.22 g of CWG for high dose of ARA, 1.33 g of 
oil high in DHA + 2.41 g of CWG for low dose of DHA, 4.0 g of oil high in DHA + 1.22 g of 
CWG for high dose of DHA. The total fat offered to animals in each treatment was: 154 g/d 
(control), 156 g/d (low ARA and DHA), 161 g/d (high ARA), and 160 g/d (high DHA). The vials 
containing the treatments were rinsed 3 times with hot water. Extra hot water was then added to 
bring the mix to a final volume of 1.89 L. Milk replacer was offered at approximately 37°C, and 
if it was too hot, the bottles were placed in a water bath to cool before being offered to heifers. 
When animals weighed less than 38 kg at birth, they were fed 0.612 kg/d of milk replacer (with 
the full lipid treatment) for 2 weeks or until they reached 38 kg of BW (whichever occurred first), 
to prevent digestive problems. During the first feeding times, a few animals refused to drink the 
full amount of milk replacer, but after the second day all animals consumed the full ration. In 
addition to milk replacer, calves had ad libitum access to water. 
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Small amounts of calf starter were introduced to the calves when they were 3 d old. 
Initially, grain bottles were provided but when heifers consumed more than 226 g/d, grain was fed 
in buckets. When animals consumed more than 2 kg of starter/d, 0.453 kg/d of alfalfa was added 
at the bottom of the bucket to help prepare the animal to transition to a silage diet after weaning. 
During the entire experiment, the amounts of starter and alfalfa offered and refused were measured 
daily.  
Weaning occurred at 63 d of age and the process lasted 7 d. Heifers were bottle fed once 
daily (1600 h) and treatments continued as previously assigned; therefore, during this week of 
weaning, milk including supplemental lipid was provided at 1/3 of the pre-weaning supply. 
Through the course of the study, 3 heifers (assigned to control, high dose DHA, and high dose 
ARA treatments, respectively) were removed from the experiment because they suffered severe 
diarrhea; 3 additional animals were enrolled at the end of the experiment to balance the number of 
animals per treatment. 
 
 Health Status 
Fecal scores were recorded twice a day following the procedure described by Karcher et 
al. (2014). Feces was scored in 5 different categories based on consistency (1 = normal and thick, 
2 = normal and less thick, 3 = thin but not watery, 4 = watery, and 5 = abnormal color) by trained 
personnel. When heifers displayed reduced intake, a listless appearance, or diarrhea, the personnel 
immediately contacted the farm management and a physical examination was performed, 
including measurement of body temperature (normal ~38.5ºC), respiration rate (normal ~50-75 
breaths/min), and heart rate (normal ~100-150 beats/min). If these parameters were abnormal and 
the abdomen looked distended, heifers were medicated with 5 mL subcutaneous and 5 mL oral 
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clostridium antitoxin as well as 5 mL of penicillin both subcutaneous and orally; this treatment 
was repeated for 3 d. If animals showed respiratory distress, they were treated with tulathromycin 
(Draxxinâ, Zoetis, Florham Park, NJ) at a dose of 1.1 mL/45 kg BW. 
 
 Performance  
Body weight was recorded every 7 d. Every Friday morning after feeding, the technicians 
moved animals to an electronic platform scale. At the same time, height at the withers and hips of 
each calf were measured with a calibrated measuring stick.  
A sample of milk replacer was collected every other week and samples were composited 
by month. A calf starter sample was collected at the end of the experiment. To determine the DM 
content of milk replacer and calf starter, samples were placed in a force-air oven at 105°C for 16 
h. The concentration of nitrogen was determined by oxidation and detection of N2 gas (Leco 
Analyzer, Leco Corp., St. Joseph, MI) and the amount of crude protein was calculated. An ether 
extraction procedure was utilized to determine the crude fat content in the samples (AOAC, 2000: 
method 920.9) and the gross energy content of milk replacer and calf starter were determined by 
using a bomb calorimeter. 
 
 Glucose and Lipid Metabolism 
Before the morning feeding (0800 h), blood samples were collected via jugular 
venipuncture on days 0, 3, 21, 30, and 63. Blood was collected in one tube with potassium EDTA 
and another containing potassium oxalate with sodium fluoride to inhibit glycolysis (Vacutainer; 
Becton Dickinson, Franklin Lakes, NJ). Immediately after collection, blood was centrifuged at 
3,000 × g for 15 min; plasma was separated and frozen at -20°C until further analysis. 
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Plasma glucose concentrations were determined by enzymatic assay (kit #439-90901; 
Wako Chemicals USA Inc., Richmond, VA). Insulin concentrations was determined with a bovine 
insulin ELISA kit (#10-1201-01; Mercodia AB, Uppsala, Sweden). Samples were placed in 
microplates containing anti-insulin antibodies bound to the plate, and peroxidase-conjugated anti-
insulin antibodies were added to the sample. The 2 monoclonal antibodies bound to insulin present 
in the sample and unbound antibody was washed out. To generate a colored product for 
measurement, 3,3’-5,5’-tetramethylbenzidine was added to the sample which reacted with the 
peroxidase, and the reaction was stopped by adding acid to the samples. 
In addition, β-hydroxybutyrate, non-esterified FA (NEFA) and triglyceride (TG) 
concentrations were determined for plasma samples to monitor the effect of treatments on these 
lipid metabolism parameters. Concentrations of β-hydroxybutyrate were determined 
enzymatically (#H7587-58; Pointe Scientific Inc., Canton, MI). A 2-reagent blend containing D-
3-hydroxybutyrate dehydrogenase, diaphorase enzymes, NAD and 4- iodonitrotetrazolium violet  
(INT) were combined and added to plasma samples. β-hydroxybutyrate reacted with NAD first 
and generated NADH; this product, in contact with diaphorase and INT, produced the reduced 
form of INT was measured by absorption at 505 nm.  
Quantification of NEFA was also done using an enzymatic procedure (NEFA-HR; Wako 
Chemicals USA Inc.). Samples were combined with acyl-CoA synthetase to conjugate NEFA to 
coenzyme-A. Then acyl-CoA oxidase was added to generate hydrogen peroxide which, in presence 
of peroxidase and 4-aminoantipyrine, generated 3-methyl-N-ethyl-N-(b-hydroxyethyl)-aniline, 
measured by colorimetry at 550 nm. 
The concentration of triglycerides in plasma samples was estimated after a sequence of 
enzymatic reactions (#H7587-01; Pointe Scientific Inc., Canton, MI). In short, plasma samples 
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were combined in wells with a combination of reagents (mixture of lipase, glycerol kinase, 
glycerol phosphate oxidase, and peroxidase). Lipase separated the FA from the glycerol backbone, 
which was converted to glycerol-1-phosphate by glycerol kinase. The enzyme glycerol phosphate 
oxidase reacted with glycerol-1-phosphate to produce hydrogen peroxidase. The non-enzymatic 
compounds present in the reagent (4-chlorophenol, 4-aminophenazone) reacted with the hydrogen 
peroxide produced previously and generated a color complex that was read colorimetrically at 500 
nm. A spectrophotometer (PowerWave XS; BioTek Instruments Inc., Winooski, VT) was utilized 
to read absorbance and with the help of Gen5 software (BioTeck Instruments Inc.). 
 
 Antibody Titers 
To stimulate the development of memory B cells, heifers were vaccinated with BoviShield 
Gold FP5 (Zoetis) on d 49 to 56 and with BoviShield Gold Plus Ultravac-7 (Zoetis) on d 63 to 70. 
Vaccinations occurred on Tuesdays after the morning feeding for any heifers that fell within the 
age windows listed. On d 49 (prior to initial vaccination), 14 days after 1st vaccination, immediately 
prior to 2nd vaccination, and 10-14 days after 2nd vaccination, subsamples of blood were collected 
and sent to the KSU-Veterinary Diagnostic Laboratory to measure the antibody titer for 3 vaccine 
strains covered in BoviShield Gold FP5: bovine respiratory syncytial virus (BRSV) and bovine 
viral diarrhea types 1 and 2 (BVD).    
The principle of the serum neutralization test is the inhibition (or neutralization) of viral 
replication by the presence of specific antibodies. Serum samples were serially diluted and mixed 
with known virus. Cultured cells were then added to this mixture and incubated to allow viral 
replication within the cells. If the test serum contained antibodies to the virus, the virus was 
neutralized, or unable to replicate, thus allowing cells to grow and monolayer normally. If the test 
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serum did not contain antibodies, the virus was allowed to replicate, thus damaging the cells and 
producing a visible cytopathic effect (CPE) in the monolayer. By making serial dilutions of test 
serum, the relative amount of antibody contained in the serum was determined and was given as a 
titer result. The highest dilution that produces neutralization was reported as the titer (Hanzlicek, 
2016). 
 
 Inflammatory Mediators 
Blood was sampled 1 d post-vaccination to determine the effect of the treatments on 
concentrations of haptoglobin and TNFα. Haptoglobin concentration was analyzed using a 
colorimetric method based on peroxidase activity (Cooke and Arthington, 2013). Tumor necrosis 
factor α was analyzed using an ELISA method (Farney et al., 2011). 
 
 Preparation of PBMC 
On d 39 ± 3 (pre-vaccination), ~51 (9 ± 3 d post-vaccination), and ~70 (7 ± 3 d post-
vaccination), 30 mL of blood was collected from the jugular vein into 4 ml of acid citrate dextrose. 
Bovine peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation from 
buffy coat fractions, and red blood cells were removed using hypotonic lysis. Cells were washed 
and re-suspended in complete RPMI (cRPMI) composed of RPMI-1640 (Gibco, Carlsbad, CA) 
supplemented with 25 mM HEPES buffer, 2 mM L-glutamine, 1% antibiotic-antimycotic solution, 
1% non-essential amino acids, 2% essential amino acids, 1% sodium pyruvate, 50 µM 2-
mercaptoethanol, and 10% fetal bovine serum.  
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 Stimulation of PBMC 
For T lymphocyte proliferation assays, PBMC were labeled with Cell Trace Violet per 
manufacturer’s recommendations (Invitrogen, Life Technologies), plated at a concentration of 
4×106 cells/mL in cRPMI (100 µL/well) in sterile, round-bottom, 96-well tissue-culture-treated 
plates (BD Biosciences), and then cultured for 6 d at 37°C in 5% CO2. For experiments using heat-
killed BRSV Strain 375 or BVD Type 2 Strain 28508-5, virus stock was inactivated for 60 min at 
56°C, then 50 µL was added to the cultures (final volume of 200 µL/well). Stimulation with poke 
weed mitogen was used as a positive control in the proliferation experiments.  
 
 Flow Cytometry 
For surface staining, cells were re-suspended at 107 cells/mL in fluorescence-activated cell 
sorting buffer and incubated for 20 min on ice with 10 µg/mL primary antibodies: mouse anti-
bovine CD4 (clone ILA11A, isotype IgG2a), all mouse anti-bovine CD3 (clone MM1A, isotype 
IgG1), mouse anti-bovine CD8 (clone BAQ111A, isotype IgM), mouse anti-bovine γδ T cell 
receptor (Clone GB21A, isotype IgG2b). All antibodies were obtained from the Washington State 
University Monoclonal Antibody Center (Pullman, WA). Cells were washed once and re-
suspended at 107 cells/mL with 5 µg/mL secondary antibodies: goat anti-mouse IgG1-AF647, goat 
anti-mouse IgG2b-PECy7 (both from Southern Biotech, Birmingham, AL), goat anti-mouse 
IgG2a-AF488 (from Life Technologies, Eugene, OR), and goat anti-mouse IgM-PE (from 
Invitrogen, Frederick, MD). Peripheral blood mononuclear cells (PBMC) were incubated for 20 
min on ice, washed, and fixed in BD FACS lysis buffer. Flow cytometry data were collected on a 
BD LSR Fortessa X-20 flow cytometer and analyzed using FLowJo software (TreeStar, San 
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Carlos, CA). Background proliferation was corrected for by subtracting the number of cells that 
divided in mock cultures from the number of cells that divided in stimulated cultures.  
 
 Statistical Analysis 
A complete randomized block design was used in this study. The data collected in this 
experiment were analyzed with the MIXED procedure of SAS (version 9.3.1, SAS Institute, Cary, 
NC) to evaluate the fixed effects of the supplemental FA, time, and treatment by time interaction. 
Models included the random effect of animal within block. The Kenward-Rogers method was used 
to estimate the denominator degrees of freedom. With an autoregressive covariance structure 
(AR[1]), repeated measures over time within heifer were modeled. Contrasts were used to evaluate 
differences between ARA and DHA (coefficients -0.6666 -0.3333 0 0.6666 0.3333) and the effect 
of different doses of these PUFA (coefficients 0.5 0 -1 0.5 0). Significance was declared at P < 
0.05 and tendencies at P < 0.10. 
 
 Results and Discussion 
 Production and Health Parameters 
Samples of milk replacer, white grease choice, and the 2 oils with high content of omega-
3 polyunsaturated FA were analyzed to determine the total and individual concentration of each 
FA; this information is detailed in Table 2.1. The oils used as source of supplemental EFA had 
concentrations of > 40% ARA and DHA, respectively. Additionally, the ratio of omega-6:omega-
3 FA for each treatment was: 14.2:1 for control, 7.4:1 and 3.7:1 for the low and high dose of DHA, 
and finally 15.2:1 for low ARA and 17.4:1 for high ARA treatments.  
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The experiment was not designed to evaluate differences in growth of calves when they 
were supplemented with omega FA. Rather it was designed to test mainly differences in glucose 
and lipid metabolism and immune function. 
On average, calves weighed 38.2 kg (SEM = 1.28 kg) at birth; this parameter was not 
different across treatments (P > 0.1). The effect of supplementing milk replacer with DHA and 
ARA on DMI, ADG and feed efficiency (FE) can be observed in Table 2.2. Total DMI was 
calculated by adding the consumption of milk replacer and calf starter (DM basis). This parameter 
was not affected either by the composition of EFA or the total supply of EFA; however, animals 
had greater consumption of DM as time passed (P < 0.05).  
Previously, no changes in total DMI were observed when total fat content of milk replacer 
was below 23% but when the fat concentration was 30%, DMI was depressed (Tikofsky et al., 
2001). In this experiment, the diets did not reach a fat content that would be expected to impair the 
appetite or development of the calves. The mean total DMI for this experiment was 2.0 kg/d, which 
was larger than that observed by Bowen Yoho et al. (2013). This group reported 0.971 kg DMI/d 
in an experiment designed to determine the effect of changing the FA profile in milk replacer with 
coconut oil as source of essential FA; however, their animals were weaned at 56 d whereas our 
heifers were weaned at 63 d.  
Overall means for ADG and feed efficiency (ADG/DMI), were 0.75 kg/d (SEM = 0.046 
kg/d) and 43.3% (SEM = 2.3%) respectively. No differences were detected for either variable 
when ARA or DHA were supplemented to young animals. A time effect was observed in both 
cases. The animals enrolled in this trial appeared to grow normally and did not exhibit any major 
health issues. 
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Similar to our results, (Ballou and DePeters, 2008) did not observe improvements in BW 
gain when they supplemented 2% fatty acid using fish oil alone or mixed with a blend of canola 
oil and corn oil. In contrast, greater ADG were observed in animals fed high concentration of 
linoleic acid (46.3 % of total FA) compared to those fed low doses (40.8% of total FA; Garcia et 
al., 2014).  
The number of days with feces classified as abnormal did not differ with EFA supply but 
differences (P < 0.05) between ARA and DHA were observed. Calves supplemented with ARA 
excreted feces with less normal consistency than animals fed DHA (Table 2). None of the animals 
suffered severe fecal abnormality and none of the animals had any fecal score greater than 3 in the 
scale used in this experiment. Karcher et al. (2014) reported no differences in the number of days 
with abnormal fecal score when they compared the supplementation of n-3 FA from fish and flax 
oils on cytokine gene expression and growth of milk-fed Holstein calves. 
 In addition to BW, changes in body conformation were determined by measuring height at 
withers and hips and the width between hips and pins were reported as changes after 63 d and also 
weekly changes (Tables 2.3 and 2.4). For animals supplemented with DHA, changes in height at 
withers were greater (P < 0.05) than for animals supplemented with ARA. Changes in width at the 
pin bones were greater (P < 0.05) when calves received low EFA than those fed with high EFA 
after 63 d on treatments. Treatments did not produce any effects on BW, hip height or hip width. 
When the aforementioned variables were analyzed for changes on a weekly basis (Table 
2.4), the majority of them were characterized by time effects (P < 0.05) except for changes in pin 
bone width and hip height.  Additionally, a significant treatment by week interaction (P <0.05) 
was detected for change in hip height and DHA tended (P < 0.10) to produce greater change in 
height at hips and withers than ARA.  
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 Glucose and Lipid Metabolism 
Variables involved in glucose and lipid metabolism are detailed in Table 2.5 and Figures 
2.2 to 2.5. The treatments fed to calves during the pre-weaning period affected plasma glucose and 
plasma non-esterified fatty acid concentrations. The glucose levels in animals fed the control 
treatment averaged 116 mg/dL (SEM = 4.75). The inclusion of ARA and DHA significantly (P < 
0.05) reduced glucose by 17% and 14%, respectively. Glucose concentration increased when the 
dose of PUFA increased (P < 0.05).  
Garcia et al. (2015) observed a quadratic effect on plasma glucose concentration with 
increasing consumption of soybean oil, as a source of polyunsaturated FA, by pre-weaned calves. 
The authors attributed this effect to the activation of the peroxisome proliferator-activated receptor 
(PPAR-g) in liver which stimulates β-hydroxybutyrate and glucose metabolism. Conversely, 
Litherland et al. (2010) performed an experiment with dairy calves to determine the effect of 
PPAR-g agonists (such as omega-3 FA) on fatty acid metabolism and did not see changes in plasma 
glucose, NEFA, or β-hydroxybutyrate concentrations. In a study where 1,200 mg of omega-3 FA 
were given to women with polycystic ovary syndrome, glucose and insulin concentrations were 
decreased, suggesting an increase in insulin sensitivity (Rafraf et al., 2012); however, insulin 
concentrations were not measured in our study. 
 The addition of 1.6 g/d of DHA decreased (P < 0.05) NEFA concentration by 40% 
compared to control, whereas the high dose of the same fatty acid reduced NEFA concentration 
by 7%. The concentration of triglycerides in plasma was not affected (P > 0.1) by the treatments.  
 The concentration of glucose decreased (P < 0.05) during the first 30 d after peaking the 
first 3 d, and then increasing from d 30 to d 63. Non-esterified fatty acids and triglyceride 
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concentrations were high during the initial 3 d, similar to what happened with glucose, but they 
declined (P < 0.05) beyond this point. Meanwhile, β-hydroxybutyrate followed the opposite trend, 
with a drop in the first 3 d and then an increase toward d 63.  
 The reduction in plasma NEFA concentration when DHA was supplemented at a low dose 
was interpreted to suggest that this fatty acid has an important role in lipid metabolism. The 
reduction of NEFA caused by DHA was not used for the formation of circulating TG, because 
despite the reduction of free FA in plasma, TG concentration did not change; von Schacky et al. 
(1985) found that EPA and DHA supplemented to humans were incorporated into phospholipids 
and the concentration of plasma TG decreased over time. Based on this observation, plasma NEFA 
may have been utilized for the formation of phospholipids in the current study. Conversely,  
Mashek et al. (2002) observed that DHA and EPA have poor rates of incorporation into cellular 
phospholipids when they evaluated the effect of different FA on glucose and lipid metabolism of 
bovine hepatocytes.  
 
 Inflammatory and Immune Response 
Omega-3 and omega-6 FA are compounds associated with inflammatory responses; the 
group with the double bond in n-3 position tends to have anti-inflammatory effects, whereas the 
n-6 group stimulates inflammation (Karcher et al., 2014).  
Adding DHA and ARA at different concentrations in this study did not impact (P > 0.10) 
the plasma concentrations of TNFα or haptoglobin (Table and Figure 2.6), both mediators of 
inflammation (Li et al., 2014). A significant time effect (P < 0.05) was observed for haptoglobin 
but not for TNFα. Hill et al. (2011) observed that the mRNA abundance of TNFα, measured in 
whole blood samples, decreased after vaccination when linoleic acid was supplied to Holstein 
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calves. The inclusion of omega-3 FA in pig diets reduced the concentration of TNFα compared to 
animals fed a vegetable oil supplement (Li et al., 2014); authors attributed this effect the ability of 
these FA to inhibit NF-κB, an activator of inflammatory gene transcription in the nucleus.  
 Figures 2.7 and 2.8 report the effect of treatments on antibody titer production when 
animals underwent vaccination for prevention of BVD types 1 and 2 and BRSV. In this case, only 
a time effect (P < 0.05) was observed. The antibody production for d 30 was greater compared to 
d 63 and 82, possibly because the animals at that point still had large amounts of maternal 
antibodies. Studies where the effect of FA on antibody titers were measured in calves after being 
vaccinated are scarce; some of the existing references (Hill et al., 2011; Esselburn et al., 2013) 
observed increased titers to bovine BVD and PI3 in response to a lipid supplement but it contained 
animal fat, butyrate, medium chain FA and linolenic acid, and not omega-3, so comparisons with 
this study are complicated.  
The suppression of T-helper type 1 cytokine production is one of the benefits attributed to 
the n-3 PUFA (Lin et al., 2007). Proliferation assays for CD4 and CD8 lymphocytes challenged 
with BRSV and BVD were performed in samples collected on d 39 (before the vaccination) and d 
7 to 9 after vaccinations. The overall treatment effect and interaction between treatments and 
sampling times were not significant (P > 0.1) but a time effect was observed (P < 0.05; Figure 
2.9). The low percentage of CD4 lymphocytes indicated that immune function was not fully 
activated yet. The vaccination and booster activated a CD4 response to BRSV followed by the 
activation of CD8 cells; however, EFA treatments were not different than control, indicating that 
these compounds had no effect on activation of this process. Similar results were observed when 
diets enriched with DHA were fed to rats with gut-derived sepsis (Lin et al., 2007); the percentage 
of CD4 and CD8 lymphocytes were not different when treatments were compared to the control. 
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In another study, the effect of a fish oil therapy evaluated in HIV positive patients with 
hyperlipidemia did not cause any variation in CD4 cell count (Ranieri, 2007).  
 
 Conclusions 
In summary, the utilization of highly concentrated sources of ARA and DHA did not 
provide enough evidence to clarify the modulatory effect of these compounds on inflammatory 
and immune response. Polyunsaturated fatty acid lowered blood glucose and NEFA indicating a 
possible regulatory effect on glucose and lipid metabolism. 
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 Tables and Figures 
Table 2.1. Fatty acid profile of basal milk replacers and essential fatty acid supplements. 
Fatty acid (g/100g 
total FA) 
DHA-rich 
oil 
ARA-rich 
oil 
White grease 
choice 
Milk 
replacer 
C6:0 0.0 0.0 0.0 0.2 
C8:0 0.3 0.0 0.0 0.4 
C10:0 1.2 0.0 0.1 0.6 
C12:0 4.8 0.0 0.1 0.6 
C14:0 12.2 0.3 1.6 2.3 
C14:1 0.2 0.0 0.0 0.1 
C15:0 0.0 0.1 0.1 0.2 
C16:0 11.3 8.7 22.1 23.1 
C16:1 2.0 0.1 2.8 2.0 
C17:0 0.0 0.3 0.4 0.5 
C18:0 0.8 7.8 8.6 11.8 
C18:1n9t 0.0 0.1 0.2 0.2 
C18:1n10t 0.0 0.0 0.0 0.2 
C18:1n11t 0.0 0.0 0.3 0.2 
C18:1n9c 18.3 20.1 41.7 33.7 
C18:1n11c 0.1 0.4 3.2 2.3 
C18:2n6c 0.7 6.8 14.9 17.7 
C20:0 0.1 0.7 0.2 0.2 
C18:3n6 0.0 2.8 0.0 0.0 
C20:1 0.1 0.3 0.9 0.6 
C18:3n3 0.0 0.1 0.6 1.1 
CLA 9c,11t 0.0 0.0 0.1 0.1 
CLA 9t,11t 0.0 0.0 0.1 0.1 
C20:2 0.0 0.6 0.8 0.6 
C22:0 0.2 1.3 0.0 0.1 
C20:3n6 0.0 3.8 0.2 0.2 
 63 
C20:3n3 0.0 0.0 0.1 0.1 
C20:4n6 0.0 44.2 0.4 0.3 
C23:0 0.0 0.1 0.0 0.1 
C24:0  0.1 1.0 0.0 0.1 
C20:5n3 0.0 0.1 0.0 0.0 
C24:1 0.0 0.1 0.0 0.0 
C22:5n3 0.7 0.0 0.1 0.1 
C22:6n3 46.7 0.0 0.0 0.0 
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Table 2.2. Effect of supplemental DHA and ARA on performance of weaned Holstein calves 
	 Treatment  Effect 
Parameter Control DHA-Low DHA-High ARA-Low ARA-High SEM Treatment 1ARA vs DHA 
Dry matter intake, kg/d 2.03 2.06 2.10 1.87 1.95 0.154 NS NS 
Average daily gain, kg/d 0.756 0.783 0.757 0.747 0.707 0.0459 NS NS 
Feed efficiency 0.430 0.451 0.417 0.467 0.402 0.0292 NS NS 
Abnormal fecal days, n 7.83 9.67 9.83 9.67 13.5 1.689 NS P < 0.05 
1ARA = arachidonic acid, DHA = docosahexaenoic acid    
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Table 2.3. Effect of supplemental DHA and ARA on growth parameters of weaned Holstein calves after 63 d on treatments 
 
	 Treatment  Effect 
Parameter Control DHA-Low DHA-High ARA-Low ARA-High SEM Treatment 1EFA dose 
∆-Body Weight, kg 48.42 48.73 47.69 46.39 44.38 2.85 NS NS 
∆-Withers height, cm 15.01 17.25 17.75 15.04 15.29 1.09 NS NS 
∆-Hip height, cm 17.98 16.44 18.16 15.88 16.12 1.34 NS NS 
∆-Hip width, cm 7.10 7.28 7.47 7.55 6.93 0.67 NS NS 
∆-Pins width, cm 6.57 8.73 8.40 9.04 8.74 0.75 NS P < 0.05 
∆ = changes         
1Essential fatty acid         
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Table 2.4. Effect of supplemental DHA and ARA on growth parameters of weaned Holstein calves (average per week) 
	 Treatment  Effect 
Parameter Control DHA-Low DHA-High ARA-Low ARA-High SEM Treatment Treat × week 1ARA vs DHA 
Body weight gain, kg/week  5.29 5.48 5.30 5.23 4.95 0.320 NS NS NS 
∆-Withers height, cm/week 1.88 1.89 1.92 1.73 1.61 0.14 NS P < 0.10 NS 
∆- Hip height, cm/week 2.10 1.93 2.03 1.79 1.69 0.15 NS NS P < 0.05 
∆- Hip width, cm/week 0.91 0.86 0.88 0.78 0.77 0.07 NS NS NS 
∆- Pins width, cm/week 1.16 0.92 1.02 0.88 0.89 0.10 NS NS NS 
1ARA = arachidonic acid, DHA = docosahexaenoic acid 		 	      
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Table 2.5. Effect of supplemental DHA and ARA on glucose and lipid metabolites 
 
	 Treatment  Effect 
Parameter Control DHA-Low DHA-High ARA-Low ARA-High SEM Treatment 1EFA dose 
Glucose, mg/dL 115.51 97.65 99.75 93.11 98.38 4.75 P < 0.05 P < 0.05 
NEFA1, µM 258.1 153.6 239.5 254.2 245.4 29.4 P < 0.05 NS 
β-hydroxybutyrate, µM 106.89 103.26 114.62 101.64 106.56 9.94 NS NS 
Triglycerides, mg/dL 18.56 17.87 18.92 15.97 17.41 3.04 NS NS 
NEFA = non-esterified fatty acid, TG = triglycerides     
 
 
Table 2.6. Effect of supplemental DHA and ARA on inflammatory mediators 
 
	 Treatment  Effect 
Parameter Control DHA-Low DHA-High ARA-Low ARA-High SEM Treatment 
TNFα1	,pg/mL 3.46 3.73 2.91 3.59 4.18 0.73 NS 
Haptoglobin, µg/mL 165 183 153 103 149 27 NS 
1TNFα= Tumor necropsies factor       
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Figure 2.1. Change in hip height of Holstein weaning calves supplemented with 
docosahexaenoic and arachidonic acid. The X-axis represent number of weeks and Y-axis 
represent the changes in hip height measure in cm. Each treatment was supplemented during 
63 d to 6 different animals. Measures were recorded weekly. 
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Figure 2.2. Effect of supplemental docosahexaenoic and arachidonic acid on plasma glucose 
concentration. The X-axis represent number of days on the experiment and Y-axis represent 
plasma glucose concentration measured in mg/dL. Each treatment was supplemented during 
63 d to 6 different animals. Plasma samples for glucose were collected on d 0, 3, 21, 30, 50 
and 63. 
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Figure 2.3. Effect of supplemental docosahexaenoic and arachidonic acid on plasma non-
esterified fatty acid concentration. The X-axis represent number of days on the experiment 
and Y-axis represent plasma NEFA concentration measured in µM. Each treatment was 
supplemented during 63 d to 6 different animals. Plasma samples for NEFA were collected 
on d 0, 3, 21, 30 and 63. 
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Figure 2.4. Effect of supplemental docosahexaenoic and arachidonic acid on plasma β-
hydroxybutyrate concentration. The X-axis represent number of days on the experiment and 
Y-axis represent plasma β-hydroxybutyrate concentration measured in µM. Each treatment 
was supplemented during 63 d to 6 different animals. Plasma samples for β-hydroxybutyrate  
were collected on d 0, 3, 21, 30 and 63. 
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Figure 2.5. Effect of supplemental docosahexaenoic and arachidonic acid on plasma 
triglycerides concentration. The X-axis represent number of days on the experiment and Y-
axis represent plasma triglycerides concentration measured in mg/dL. Each treatment was 
supplemented during 63 d to 6 different animals. Plasma samples for triglycerides were 
collected on d 0, 3, 21, 30 and 63. 
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Figure 2.6. Effect of supplemental docosahexaenoic and arachidonic acid on tumor necrosis 
factor-α	and	haptoglobin concentration. The X-axis indicates the treatments used during 
the experiment, the Y-axis represent plasma haptoglobin concentration measured in µg/mL. 
Each treatment was supplemented during 63 d to 6 different animals. Plasma samples for 
haptoglobin were collected on d 50 and 64, one day after vaccination. 
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Figure 2.7. A) Effect of supplemental docosahexaenoic and arachidonic acid on antibody titer 
for bovine viral diarrhea type 1 (BVD1). B) Effect of supplemental docosahexaenoic and 
arachidonic acid on antibody titer for bovine viral diarrhea type 2 (BVD1).  C) Effect of 
supplemental docosahexaenoic and arachidonic acid on antibody titer for bovine respiratory 
syncytial virus. The X-axis indicates the treatments used during the experiment, the Y-axis 
represent the maximum inhibitory dilution of serum for antibody reactivity for the 
mentioned strains of virus. Each treatment was supplemented during 63 d to 6 different 
animals. Plasma samples for antibody titer were collected on d 49, 63 and 82. 
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Figure 2.8. A) Effect of supplemental docosahexaenoic and arachidonic acid on antibody titer 
for bovine viral diarrhea type 1 over time. B) Effect of supplemental docosahexaenoic and 
arachidonic acid on antibody titer for bovine viral diarrhea type 2 over time.  C) Effect of 
supplemental docosahexaenoic and arachidonic acid on antibody titer for bovine respiratory 
syncytial virus over time. The X-axis indicate sampling dates; the Y-axis represent the 
maximum inhibitory dilution of serum for antibody reactivity for the mentioned strains of 
virus. Each treatment was supplemented during 63 d to 6 different animals. Plasma samples 
for antibody titer were collected on d 49, 63 and 82. 
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Figure 2.9. Effect of supplemental docosahexaenoic and arachidonic acid on CD 4 cell proliferation in response to bovine viral 
diarrhea and bovine respiratory syncytial virus.  The X-axis indicates the sampling dates used for this analysis, the Y-axis 
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represents the percentage of cells proliferating when treatments were supplemented to Holstein calves during pre-weaning 
period. Each treatment was supplemented during 63 d to 6 different animals. 
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 Abstract 
 Positive effects on fiber degradation have been observed when supplemental cobalt (Co) was 
added to diets for ruminants but dose-dependent effects of different Co sources on ruminal 
fermentation have received little attention. Our objective was to determine the effects of different 
sources and concentrations of Co on in vitro fermentation rate, fermentation end-products, and 
DM and NDF disappearance (DMD and NDFD, respectively). Ruminal fluid was collected from 
heifers fed a high-forage diet with < 0.1 ppm supplemental Co and fermentation substrate 
contained no measurable Co. Different inclusion levels (0.0, 0.1, 0.5, 1.0, 2.0, 5.0, 10.0, and 15.0 
ppm Co) of Co glucoheptonate (CoGH) and Co carbonate (CoCarb) were tested in vitro during 
Experiment 1. Gas production was recorded every 15 min and, after 24 h, pH was measured and 
contents of each flask were used to determine DMD and NDFD. Experiment 2 evaluated the effects 
of Co (CoGH and CoCarb at 0, 0.33, 1, 3, and 9 ppm Co) on gas production, VFA concentration 
and NH3 concentrations. In both studies, each treatment combination had 4 replicates and samples 
were incubated for 24 h. Asymptotic gas production curves were modeled with the NLIN 
procedure of SAS using the Gauss-Newton fit method. Gas production kinetic values and all other 
data were modeled to assess the effects of Co concentration, source, and their interaction. 
Regardless of source, Co significantly decreased (P < 0.05) the rate of gas production in 
Experiment 1. Gas production tended to decrease (P < 0.10) more rapidly with increasing CoGH 
relative to similar levels of CoCarb. Dry matter disappearance was greater for CoGH compared to 
CoCarb across levels of Co tested. Neutral detergent fiber disappearance was increased by 21% 
for CoGH at concentrations between 0.1 and 1.0 ppm but a pronounced drop in NDFD occurred 
at 15 ppm Co for this treatment. The effects of Co source on gas production kinetics and pH change 
were inconsistent between experiments 1 and 2, largely because of dramatic effects at 15 ppm. 
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Relative to no Co supplementation, concentrations of branched chain VFA decreased (P < 0.05) 
with Co supplementation. CoCarb dose-dependently and linearly decreased (P < 0.05) the amount 
of unsaturated fatty acids and also linearly increased (P < 0.05) saturated fatty acids after 
incubation, presumably reflecting an increased extent of biohydrogenation. In the case of CoGH, 
the effect of concentration was minimal, resulting in substantial differences in FA profiles between 
the Co source at concentrations of 3 and 9 ppm. In summary, CoGH increased DMD and NDFD 
at 1 ppm Co or less relative to CoCarb but decreased NDFD at 15 ppm Co. Furthermore, CoGH 
had limited effects on the biohydrogenation of LCFA, whereas CoCarb ≥ 3.0 ppm appeared to 
stimulate this process. 
 
Key words: Minerals, Digestibility, Fiber, Gas production 
 
 Introduction 
Microbial populations in the rumen are capable of using cobalt (Co) to produce cobalamin 
and its biologically-active analogs; these compounds act as enzymatic cofactors in several 
metabolic processes such as gluconeogenesis and methionine synthesis (Kadim et al., 2003; Girard 
et al., 2009). Vitamin B12 synthesis from dietary Co occurs through a complex process that requires 
30 enzymatically-catalyzed steps to form a corrin ring, where Co is placed in the center of the 
structure and attached to 4 pyrol-derived nitrogen molecules (Raux et al., 2000). 
Despite the ability of ruminal microbes to synthesize cobalamin from Co, the process is 
inefficient and makes ruminants susceptible to Co deficiency. In the presence of adequate Co, the 
rate of conversion does not exceed 15% whereas, when the amount is low, as little as 3% is 
converted to cobalamin (Costigan and Gerdes, 1991). In addition, vitamin B12 is degraded in the 
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rumen and its absorption is reduced as a result (Costigan and Gerdes, 1991). In addition to its pro-
vitamin role, major benefits have been observed on fiber degradation when extra Co has been 
added to the diet (Kišidayová et al., 2001), perhaps in part because the divalent cation character of 
Co allows it to serve as a linkage between the negatively-charged outer plant cell wall and 
negatively-charged bacterial membranes. Inadequate levels of this mineral in rations for ruminants 
caused unstable fermentation patterns and lower apparent nutrient digestibility associated with 
shifts in microbial populations (Kadim et al., 2003). 
Some studies have tested the impact of the form of minerals on animal performance. Some 
references indicate more beneficial effects when Co is included in a chelated form (Formigoni et 
al., 2011), whereas others observed 10% higher bioavailability when an inorganic source of Co 
was supplied (Kawashima et al., 1997). More recently, a study reported that when fed at 10 times 
NRC (2001) recommendations, both Co forms seem to have similar effects compared to a control 
diet containing the recommended concentration of Co (Akins et al., 2013).  
The objective of this study was to determine the effects of Co carbonate (CoCarb) and Co 
glucoheptonate (CoGH) levels on in vitro fermentation rate, DM disappearance, fiber degradation, 
fermentation end-products, and fatty acid biohydrogenation.  
 
 Materials and Methods 
All the experimental procedures were approved by Kansas State University Institutional 
Animal Care and Use Committee. 
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 Experiment 1: Evaluation of Fermentation Response to Varying Inclusion Levels of 
Cobalt Glucoheptonate and Cobalt Carbonate In Vitro 
For this experiment, 3 cannulated Holstein heifers were used as ruminal fluid donors. These 
animals were housed in tie-stalls at the Kansas State University Dairy Cattle Teaching and 
Research Unit and fed a high-forage diet (Table 3.1) with minimal supplemental Co (< 0.1 ppm as 
Co carbonate). Before any collection of rumen fluid, heifers were fed this diet for a 14-d adaptation 
period to reduce the possible carryover of Co from the previous diet. The animals were fed once  
daily.  
Ruminal liquor was collected from the 3 animals, composited and placed into a preheated 
thermal recipient to maintain temperature during transportation. In the laboratory, ruminal fluid 
was strained through 8 layers of cheesecloth and placed into a large separatory funnel, which was 
maintained at 37°C for 30-40 min to allow for stratification of the mat, fluid, and protozoal 
fractions. The protozoa-rich fraction was voided from the funnel and the clarified liquid layer was 
mixed 1:2 with McDougall’s buffer.  
The basal substrate was composed of corn silage (22%), alfalfa hay (21%), corn grain 
(25%), cottonseed (4%), dried distiller grains (14%) and soybean meal (14%). These materials 
were dried and ground through a 1-mm screen and subsequently blended into the appropriate 
proportions. Standard proximate chemical analyses and mineral analyses were conducted to 
characterize the substrate composition via wet chemistry. This mixture (2.5 g) was added to each 
fermentation flask, which was equipped with pressure sensitive membranes and RF transmitters 
that recorded the volume of fermentative gasses produced at 15-min intervals (RFS Gas Production 
System, Ankom Technologies, Macedon, NY).  
The experimental treatments consisted of 2 different sources of Co: CoGH (chelated; 
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COPRO® 25, Zinpro Corporation, Eden Prairie, MN; CoGH) and feed grade CoCarb (inorganic; 
Akins et al., 2013). Each source was evaluated at 8 different inclusion levels: 0, 0.1, 0.5, 1.0, 2.0, 
5.0, 10.0, and 15.0 ppm Co (w/v based on 150 mL of ruminal inoculum). Glucose was also added 
to the CoCarb treatments such that the total mass added was uniform across sources of Co for each 
concentration (0, 0.8, 4.1, 8.2, 16.3, 40.8, 81.6, and 122.4 mg glucose / flask, respectively). Each 
treatment combination was added to 4 different flasks (4 repetitions / treatment; 64 treatment flasks 
in total). Sources and levels were randomly distributed within the incubator to avoid any effect of 
location on overall treatment estimates. 
Finally, 150 mL of the ruminal inoculum was added to each flask. Four flasks contained 
inoculum only and were treated as blanks. Gas (CO2) was used to remove oxygen from the flasks 
and then the flasks were placed in an incubator at 39°C for 24 h. The tubes were gently swirled 
every 3 to 4 h during the incubation. 
After 24 h of fermentation, the pH of the solution in each flask was measured and contents 
of the flasks were chilled in an ice bath to cease microbial activity. The solution was weighed and 
put in aluminum pans. The pans were placed in a 55°C oven for 48 h to determine DM content. 
The remaining material was used to determine the concentration of NDF in the presence of sodium 
sulfite and amylase (Van Soest et al., 1991) with an Ankom Fiber Analyzer (Ankom Technology, 
Fairport, NY).  
 
 Experiment 2: Effects of Cobalt Glucoheptonate and cobalt carbonate on VFA 
Yield and Long Chain Fatty Acids Biohydrogenation During In Vitro Fermentation 
The extraction of rumen fluid and its preparation were identical to the procedure followed 
during Experiment 1. The treatments for this experiment were chosen based on gas production, 
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pH, and DMD obtained from the previous study. Treatments, which were applied as in Experiment 
1, provided 0, 0.33, 1, 3, and 9 ppm Co (w/v based on 150 mL of ruminal inoculum), with glucose 
again added to CoCarb to equalize the total mass added across treatments. Four replicates were 
included for each treatment (40 treatment flasks total). 
At the end of fermentation (24 h), pH was measured, and the contents of the flasks were 
chilled in an ice bath to cease microbial activity. A 10-mL sample was centrifuged at 30,000 × g 
for 20 min and a 4 mL sample of supernatant was combined with 1 mL of metaphosphoric acid for 
storage at -20ºC. These samples were used to characterize concentrations of VFA (HACH. 2000) 
and NH3 (Broderick and Kang, 1980). Another 10 mL was utilized to characterize concentrations 
of long-chain fatty acids (LCFA) by GC analysis (Sukhija and Palmquist, 1988). 
 
 Data Analysis 
Asymptotic gas production curves were modeled with the NLIN procedure of SAS (version 
9.3, SAS Institute, Cary, NC) using the Gauss-Newton fit method (Schofield et al, 1994). 
Individual flask data were modeled to determine the lag phase, gas production rate, and asymptote; 
these values were subsequently evaluated as dependent variables. Gas production kinetic values 
and all other data from each flask were evaluated using the MIXED procedure of SAS to evaluate 
the effects of Co concentration, source, and their interaction (SAS Institute Inc., 2011). Contrasts 
were then used to evaluate the overall effect of Co supplementation compared with control, the 
overall effect of source, the linear and quadratic responses to concentration, and the linear and 
quadratic interactions of concentration and source. Source and concentration effects are shown 
independently unless there was evidence of an interaction. 
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 Results  
 Experiment 1 
The basal substrate utilized in these experiments contained 21.5% CP, 3.97% ether extract, 
24.8% NDF, and 18.9% ADF (DM basis). The Co concentration in the basal substrate was less 
than the detection limit of 1 ppm (Method EPA 6010) and therefore provided little background Co 
(less than 0.017 ppm in final solution). 
Effects of treatments on gas production are shown in Table 3.2. Cobalt supplementation 
decreased the rate of gas production compared to control and tended to increase the lag time 
between inoculation and commencement of gas production. The asymptotic total 24-h gas 
production tended to decrease more rapidly for CoGH as concentrations increased (linear dose by 
source interaction, P < 0.10) and CoGH also decreased gas production rate compared to CoCarb 
(P < 0.05). Level of Co did not affect pH change; however, CoGH caused less change (P < 0.05) 
in pH relative to CoCarb (Table 3.2). 
In vitro DMD and NDFD of basal substrate, as affected by Co treatments, is presented in 
Figure 3.1. There was a trend for a linear decrease (P < 0.10) in DMD as Co levels increased. In 
addition, CoGH (P < 0.05) increased DMD compared to CoCarb (63.8 ± 1.23% vs. 61.3 ± 1.24% 
across all levels); however, no interaction (P > 0.10) between concentration and source was 
observed.  
A significant interaction between source and level was observed for NDFD, at Co 
concentrations of 0.1 to 1.0 ppm, CoGH increased (P < 0.05) NDFD by 21% (60.2 vs. 49.8%, SE 
= 2.54%) compared to similar levels of CoCarb but CoGH levels >1.0 ppm led to a decrease in 
NDFD. In fact, when CoGH was supplemented at 15 ppm Co, only 15% of NDF was degraded.  
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 Experiment 2 
Relative to no Co supplementation, the rate of gas production during Experiment 2 
decreased (P < 0.05) with the addition of CoCarb and CoGH (Table 3.3) and a similar effect was 
observed for the asymptotic volume of gas produced. There was no evidence that different 
concentrations of Co affected the lag component of the cumulative gas production curve; however, 
lag time was increased (P < 0.05) by CoGH compared to CoCarb (219.8 vs. 199.3 min, SE = 6.15).  
Regardless of Co source, increasing Co concentrations linearly reduced pH change (Table 
3.4). In this experiment, a source effect on pH was not observed as in Experiment 1. Supplementing 
Co decreased in vitro ammonia concentrations compared to control (25.5 vs. 24.7 mM, SE = 
0.55mM; P < 0.05; Table 3.4). Ammonia concentrations were approximately 25 mM with the 
addition of 0.33 to 3.0 ppm but decreased to approximately 23 mM at 9.0 ppm Co (quadratic, P < 
0.05). Individual and total concentrations of VFA are also shown in Table 3.4. Relative to the non-
supplemented control, concentrations of valerate and branched chain VFA (isobutyrate, and 
isovalerate) decreased with Co supplementation (P < 0.05). Concentrations of acetate, isobutyrate, 
and isovalerate decreased in a quadratic manner as supplemental Co increased (P < 0.05).  
Results of LCFA profile analysis following 24 h of in vitro incubation revealed numerous 
interactions between source and level of Co (P < 0.05; Supplemental Table 1). To better understand 
the effect of added Co source and levels on the biohydrogenation of fatty acids, the LCFA were 
grouped into 5 different categories: polyunsaturated fatty acid (PUFA), unsaturated fatty acid 
(UNS), saturated fatty acids (SAT), trans-fatty acids (TRANS), and conjugated linoleic fatty acids 
(CLA). The effects of Co on these categories of LCFA are shown in Figure 3.3. These graphs show 
how the interaction between levels and sources of Co modified the relative proportion of UNS and 
SFA. CoCarb linearly decreased (P < 0.05) PUFA and UNS concentrations and also linearly 
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increased SAT concentrations, presumably reflecting an increased extent of biohydrogenation. In 
the case of CoGH, the effect of concentration was minimal, resulting in substantial differences in 
FA profiles between Co sources at concentrations of 3 and 9 ppm. Compared to profiles in the 
control treatment (Fig. 3.3, Supplemental Table 1), levels of CoCarb > 1.0 ppm seemed to promote 
biohydrogenation. 
 
  Discussion 
The animals used as rumen fluid donors in these experiments were fed a high-forage diet. 
Existing evidence indicates that in vitro digestibilities of DM, OM and NDF were improved when 
substrate was incubated with inoculum obtained from animals fed only with alfalfa compared to a 
higher concentrate diet (Hussein et al., 1994). 
The NRC (2001) estimated 20 ng/mL (ppb) as the critical concentration of Co in ruminal 
fluid for adequate vitamin B12 production (maintaining tissue concentrations of vitamin B12 > 0.3 
µg/L). Results in this study clearly demonstrate responses to Co supplementation at higher levels, 
likely independent of vitamin B12 synthesis. In general, ruminal Co concentrations are 
approximately 80% of dietary Co concentrations (Kirsten et al., 2008; Suttle, 2010). Therefore, 
the treatments in this study are relevant for predicting responses to dietary Co ranging from 0 to 
18.75 ppm. 
Across both experiments, supplemental Co lowered the rate of gas production by almost 
6% in comparison with the control; however, the effects of Co source on the kinetics of gas 
production were inconsistent across experiments. In Experiment 1, CoGH decreased the rate of 
gas production but in Experiment 2 this outcome was not observed. On the other hand, the lag time 
was affected by source in Experiment 2 but not during Experiment 1. Another in vitro study, 
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performed with rumen fluid from goats, showed a greater rate of gas production when 0.35 ppm 
of Co (in the form of CoSO4•7H2O) was added to the substrate (Nasser, 2013). These results are 
not in agreement with the kinetics of gas production obtained in our study and may be due to 
differences in the form of Co used. 
In contrast to the gas production results, the in vitro DMD and NDFD responses suggested 
that moderate levels of supplemental Co improved ruminal degradation of substrate. In an 
experiment with cannulated lambs (Bishehsari et al., 2010), increasing concentrations of Co (0, 
0.25, 0.50, 0.75 and 1.0 ppm as CoSO4•7H2O) improved the degradation of DM. In a separate 
study using similar concentrations, DM disappearance was greater at the intermediate 
supplementation levels, whereas low levels of Co (0.1 and 0.12 ppm as CoSO4•7H2O) decreased 
the apparent nutrient digestibility (Wang et al., 2007). Results of DMD and NDFD analyses in 
Experiment 1 were similar to the results described in these references, although the effect of dose 
for DMD was marginal (P = 0.06). Maximal digestibility of both DM and NDF was achieved at 
0.1 to 0.5 ppm Co.  
CoGH significantly increased DMD relative to CoCarb in Experiment 1, seemingly in 
direct contrast to the decrease in gas production rate by CoGH. The results for NDFD suggest that 
the rumen availability of Co was higher in the CoGH because at levels between 0.1 and 1.0 ppm, 
NDFD was greater for CoGH but declined sharply at 15 ppm Co with this source. These responses 
align with the results of Kawashima et al. (1997), who indicated that Co glucoheptonate had higher 
solubility than Co carbonate.  
Several authors have concluded that Co augments the digestion of the fiber fraction by 
increasing the activity of fibrolytic bacteria (Scott and Dehority, 1965; Bishehsari et al., 2010; 
Nasser, 2013). Two different studies measured effects on microbial activity; one (Nasser, 2013) 
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observed higher protozoal populations at 1.0 ppm Co (CoSO4•7H2O) and the other (Kišidayová et 
al., 2001) found a significant 10% increase in cellulose digestibility with supplemental Co 
(CoSO4). These findings also agree with an early publication (Scott and Dehority, 1965) which 
claimed that cellulolytic bacteria such as Ruminococcus flavefaciens need vitamin B12 for maximal 
growth. 
Vitamin B12 is an essential cofactor of methylmalonyl CoA mutase, which is required in 
the fermentative conversion of succinate to propionate (Takahashi-Iñiguez et al., 2012). There is 
evidence that supplemental Co can augment the activity of microbial methylmalonyl CoA mutase 
(Tiffany et al., 2006). This is supported by Costigan and Gerdes (1991), who reported that 
Selenomonas ruminantium, a ruminal species that has propionate as its major end-product, showed 
greater uptake of Co when ionic Co-60 was added to the medium. In another study with Prevotella 
ruminicola 23, concentrations of succinate and acetate were higher when vitamin B12 was absent 
but, when the vitamin was included, a higher concentration of propionate was observed (Strobel, 
1992). It is important to consider that the methylmalonyl CoA mutase reaction is not the only 
mechanism in the rumen to generate propionate (Tiffany et al., 2006).  
Previous research demonstrated greater production of propionate with CoGH compared to 
Co propionate at the same levels of supplemental Co (Tiffany et al., 2003). We found no 
differences in VFA profiles between Co sources in the current experiments, nor did Co 
concentration impact propionate concentrations. Our findings do not support proposed impacts of 
Co on propionate production, perhaps in part due to low basal concentrations of Co in the substrate, 
which may have been adequate to support sufficient vitamin B12 concentrations.  
Two of the three studies that have evaluated the effects Co on branched chain fatty acid 
and ammonia concentrations in vitro have found no changes in these parameters (Stemme et al., 
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2008; Nasser, 2013), although they added less than 1 ppm Co (CoSO4) to the inoculum in these 
studies. Another report found increasing amounts of isobutyrate when Co was supplemented at 4 
ppm (Kawashima et al., 1997). The decrease in isobutyrate and isovalerate concentrations in 
response to Co supplementation in Experiment 2 did not agree with these previous findings. In 
contrast, the response we detected was driven primarily by inhibitory effects observed only at 3 
ppm Co and greater. These results, accompanied by the decrease in NDFD at high concentrations 
of CoGH, may indicate that excessive amounts of Co can be detrimental for ruminal microbes, 
especially with highly soluble sources.  
 The results obtained in this study in regard to the concentration of LCFA differ from a 
previous report that did not find differences in LCFA molar proportions when Co (CoCO3) was 
added between 0.05 and 1.0 ppm (Tiffany et al., 2006). Another study, conducted to test whether 
different oral doses of Co acetate (3, 6 and 9 ppm) affected production parameters and ruminal 
function in lactating sheep (Frutos et al., 2014), revealed no changes in the ruminal concentrations 
of LCFA or bacterial populations. By looking at the categories of the LCFA, our outcomes suggest 
an impact of added CoCarb on the microbes involved in the biohydrogenation of fatty acids. At 
high levels of CoCarb inclusion, the shift in LCFA profile from UNS to SAT fatty acids was 
consistent with an increase in the extent of biohydrogenation after 24 h of incubation; furthermore, 
the biohydrogenation pathway that produces trans-10, cis-12 CLA as an intermediate is associated 
with milk fat depression (Griinari et al., 1998). The concentration of this FA linearly decreased 
with increasing CoCarb supplementation. Although these effects occurred at concentrations that 
showed alterations in ammonia and branched-chain fatty acid concentrations, these measures did 
not differ by source as LCFA did, making it difficult to propose a mechanism underlying this 
response. 
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 Conclusions 
Results of Experiments 1 (NDFD) and Experiment 2 (branched-chain VFA) appear to 
indicate that Co concentrations in the 9 to 15 ppm range have negative effects on in vitro 
fermentation. For NDFD in particular, CoGH had a stimulatory effect at moderate concentrations 
(0.1 to 1.0 ppm) but clearly inhibited NDFD at a concentration of 15 ppm. Overall, CoGH 
increased DMD relative to CoCarb. Source effects on gas production kinetics and pH change 
during fermentation were inconsistent between Experiments 1 and 2 because of dramatic effects 
of 15 ppm CoGH in the first study, though source by concentration effects were not significant for 
these variables. Finally, CoCarb enhanced FA biohydrogenation at Co concentrations of 3 ppm 
and greater. 
Overall, our results suggest that Co does impact ruminal fermentation. Considering all of 
the outcomes we measured, the optimal response for ruminal microbes appears to be achieved with 
as little as 0.1 to 0.5 ppm Co. In that range of concentrations, CoGH enhanced DMD by 6% units 
and NDFD by 18% units whereas CoCarb increased DMD by 5% units and NDFD by 7% units 
relative to no Co supplementation. 
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 Tables and Figures 
Table 3.1. Ingredient and nutrient composition of the diet fed to the ruminally-
cannulated heifers during Experiment 1 and 2.  
Item %, DM basis 
Ingredient  
Wheat straw 36.91 
Alfalfa hay 23.05 
Corn grain, ground 21.73 
Corn distillers grain, dried 17.93 
Soybean meal   0.87 
Trace mineral salt1   0.13 
Vitamin A premix     0.0091 
Vitamin D premix     0.0297 
Vitamin E premix     0.0800 
Nutrient  
DM, % as fed 60.6 
CP 11.9 
NDF 48.5 
ADF 32.3 
EE  2.5 
NFC 31.8 
1Provided 50 ppm Co, 300 ppm Cu, 2000 ppm Fe, 70 ppm 
I, 2000 ppm Mn, 3500 ppm Zn 
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Table 3.2. Effect of different sources and concentrations of cobalt on in vitro 
asymptotic volume (V), rate (K), lag phase (L) of cumulative gas production curves 
and pH changes during Experiment 1. 
Treatment V, mL K, mL/min L, min pH change 
No supplemental Co 222.7 0.0031 192.4 -0.710 
CoCarb (Co, ppm)     
0.1 222.8 0.0030 208.9 -0.713 
0.5 222.8 0.0030 187.7 -0.695 
1.0 216.1 0.0031 199.4 -0.763 
2.0 213.5 0.0030 198.8 -0.753 
5.0 221.0 0.0028 196.3 -0.655 
10.0 222.5 0.0030 201.8 -0.735 
15.0 209.1 0.0031 204.7 -0.745 
CoGH (Co, ppm)         
0.1 219.8 0.0030 200.2 -0.725 
0.5 224.4 0.0029 206.2 -0.680 
1.0 220.6 0.0028 203.6 -0.680 
2.0 218.9 0.0030 191.2 -0.693 
5.0 218.6 0.0028 201.7 -0.675 
10.0 213.9 0.0028 194.9 -0.658 
15.0 210.5 0.0028 196.1 -0.703 
SE 6.66 0.0001 6.15 0.029 
Contrast1 e AB a B 
1A = No supplemental Co vs. all other treatments; B = source effect; C = linear dose; D = 
quadratic dose; E = linear dose × source; F = quadratic dose × source; Upper case = P < 
0.05; lower case = P < 0.10. 
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Table 3.3. Effect of different sources and concentrations of cobalt on in vitro 
asymptotic volume (V), rate (K), and lag phase (L) of cumulative gas production 
curves and pH changes during Experiment 2 
Treatment V, mL K, mL/min L, min 
No supplemental Co 230.80 0.0035 205.11 
CoCarb (Co, ppm)    
0.33 220.23 0.0032 183.75 
1.0 222.61 0.0034 210.39 
3.0 227.93 0.0034 200.43 
9.0 222.96 0.0033 202.72 
CoGH (Co, ppm)    
0.33 227.53 0.0033 216.20 
1.0 214.2 0.0032 215.39 
3.0 224.07 0.0033 213.97 
9.0 216.38 0.0032 233.54 
SE    5.62 0.0001  13.44 
Contrast1 A A B 
1A = No supplemental Co vs. all other treatments; B = source 
effect; C = linear dose; D = quadratic dose; E = linear dose × 
source; F = quadratic dose × source; Upper case = P < 0.05; 
lower case = P < 0.10. 
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Table 3.4. In vitro volatile fatty acid concentrations (mM), ammonia concentration (mM) and pH change with different sources 
and concentrations of cobalt in Experiment 2 
 
Treatment Acetate Propionate Butyrate Valerate Isobutyrate Isovalerate Total VFA NH3 pH change 
No supplemental Co 62.68 38.04 13.72 2.99 1.45 1.73 114.4 25.50 -0.624 
CoCarb (Co, ppm)          
0.33 61.27 38.02 13.35 2.87 1.43 1.66 112.6 25.81 -0.642 
1.0 62.04 37.85 13.43 2.91 1.46 1.69 113.3 25.26 -0.617 
3.0 62.96 38.95 13.61 2.90 1.40 1.65 115.5 25.53 -0.653 
9.0 62.07 38.40 13.54 2.86 1.30 1.53 114.0 22.60 -0.648 
CoGH (Co, ppm)                   
0.33 61.22 37.42 13.43 2.87 1.41 1.66 112.1 25.49 -0.593 
1.0 64.10 39.18 14.01 2.93 1.44 1.68 115.8 25.81 -0.631 
3.0 61.63 37.31 13.64 2.89 1.40 1.62 112.5 24.20 -0.622 
9.0 60.10 37.46 13.39 2.86 1.34 1.51 110.8 23.11 -0.643 
SE 1.37 0.53 0.23 0.05 0.03 0.03 1.9 0.55 0.039 
Contrast1 D   A ACD ACD  ACD C 
1A = No supplemental Co vs. all other treatments; B = source effect; C = linear dose; D = quadratic dose; E = linear dose × source; F = 
quadratic dose × source; Upper case = P < 0.05; lower case = P < 0.10. 
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Figure 3.1. In vitro DM and NDF disappearance with different sources and concentrations 
of cobalt.  The X-axis represent the concentration of Co expressed in ppm, and the Y-axis 
indicate the in vitro disappearance of NDF expressed as a percentage.  1A = No supplemental 
Co vs. all other treatments; B = source effect; C = linear dose; D = quadratic dose; E = linear 
dose × source; F = quadratic dose × source; Upper case = P < 0.05; lower case = P < 0.10.  
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Figure 3.2. In vitro gas production with two different sources of cobalt during Experiment 
2. The X-axis represents incubation time expressed in minutes, and the Y-axis indicate the 
quantity of gas produced for each source of Cobalt, measured in ml. 
  
SEM: 4.47 
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Figure 3.3. In vitro A) saturated fatty acid concentration (Sat), B) unsaturated fatty acid 
concentration (Unsat), C) polyunsaturated fatty acid concentration (PUFA), and D) 
conjugated linoleic acid concentration (CLA) with different sources and concentrations of 
cobalt. The X-axis represent the concentration of Co expressed in ppm, and the Y-axis 
indicate the grams of fatty acid in 100 g of total fat.  1A = No supplemental Co vs. all other 
treatments; B = source effect; C = linear dose; D = quadratic dose; E = linear dose × source; 
F = quadratic dose × source; Upper case = P < 0.05; lower case = P < 0.10. 
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Chapter 4 - Effects of supplemental chromium propionate and 
rumen-protected amino acids on productivity, diet digestibility, and 
energy balance of peak lactation dairy cattle 
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 Abstract 
Chromium (Cr) feeding in early lactation increased peak milk production in some studies, but 
responses to dietary Cr during peak lactation have not been evaluated. Furthermore, interactions 
of essential amino acids (AA) and Cr have not been explored. Our objective was to evaluate 
responses to CrPr (KemTRACE brand Chromium Propionate 0.04%, Kemin Industries, Inc.) and 
rumen-protected Lys (LysiPEARL, Kemin Industries, Inc.) and Met (MetiPEARL, Kemin 
Industries, Inc.) and their interaction in peak lactation cows. Forty-eight individually fed Holstein 
cows (21 primiparous, 27 multiparous, 38 ± 15 days in milk) were stratified by calving date in 12 
blocks and randomly assigned to 1 of 4 treatments within block. Treatments were control, CrPr (8 
mg/d Cr), RPLM (10 g/d Lys and 5 g/d Met, intestinally available), or CrPr plus RPLM. 
Treatments were premixed with ground corn and top-dressed at 200 g/d for 35 d. Diets consisted 
of corn silage, alfalfa hay, and concentrates, providing approximately 17% CP, 31% NDF, and 
40% NFC. Dry matter intake (DMI) significantly increased (P > 0.05) with the inclusion of CrPr 
(22.2 vs. 20.8 ± 0.67 kg/d), and energy-corrected milk (ECM) yield tended to increase (P = 0.09). 
In addition, CrPr increased milk protein yield and tended to increase DMI in primiparous cows but 
not in multiparous cows. A CrPr by week interaction (P < 0.05) was detected for milk lactose 
content, which was increased by CrPr during week 1 only (4.99 vs. 4.88 ± 0.036%). As a 
proportion of plasma AA, lysine increased and methionine tended to increase in response to 
RPLM, but the inclusion of RPLM decreased (P < 0.05) N efficiency (milk protein N / N intake). 
Digestible energy intake, gross energy digestibility, and energy balance were not affected (P > 
0.10) by treatments. There were no treatment effects on feed efficiency or changes in body weight 
or body condition score (P > 0.10). In summary, feeding CrPr increased DMI and tended to 
increase ECM in cows fed for 5 wk near peak lactation, with primiparous cows showing greater 
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responses in DMI and milk protein yield than multiparous cows. 
 
Key words: lysine, methionine, chromium, essential amino acid 
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 Introduction 
After parturition, cows must adapt to milk secretion, but their daily DMI rarely matches 
the nutrient demands for that activity (Dalbach et al., 2011). Because of these extremely high 
nutrient requirements, cows near peak lactation are most likely to experience AA deficiencies, 
which can limit peak milk and, in turn, decrease whole-lactation productivity.  
 Chromium (Cr) is involved in many metabolic functions (Mertz, 1993; Bryan et al., 2004); 
it activates certain enzymes and stabilizes AA and nucleic acids (National Research Council, 1997; 
Khalili et al., 2012). Some studies utilized supplemental Cr in diets for lactating cattle and reported 
increases in milk production (Hayirli et al., 2001; McNamara and Valdez, 2005), whereas others 
detected enhanced immune responsiveness and disease resistance, particularly in animals under 
stress conditions (Spears et al., 2012). 
 It is also known that Cr can potentiate the action of insulin by binding to intracellular 
insulin receptor sites and promoting signal transduction (Kegley et al., 2000), thereby enhancing 
carbohydrate metabolism. In addition, Cr can alter protein synthesis (Gentry et al., 1999); though 
the mechanisms underlying this effect are not completely understood, the impact of Cr on insulin 
sensitivity has been clearly demonstrated in cattle (Sumner et al., 2007), and insulin signaling 
promotes protein synthesis. However, there is currently no information about interactions between 
AA nutrition and Cr supplementation in dairy cattle. Therefore, a critical need exists to further 
explore responses to Cr in the presence and absence of supplemental AA near peak lactation. 
 
 Materials and Methods 
The Kansas State University Institutional Animal Care and Use Committee approved all 
experimental procedures. 
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 Design and Treatments  
Forty-eight lactating Holstein cows (21 primiparous and 27 multiparous, 38 ± 15 DIM) 
were used in a randomized complete block design with 4 treatments. The cows were stratified by 
calving date in 12 blocks, and assigned randomly to treatments within block.  
 All cows were housed in tie-stalls and individually fed a common diet (Table 4.1). Analysis 
by the Cornell Net Carbohydrate and Protein System version 6.1 (NDS version 3, Ruminant 
Management & Nutrition, Reggio Emilia, Italy) estimated metabolizable Lys supply at 148 g/d 
(6.38% of MP) and metabolizable Met supply at 47 g/d (2.03% of MP) with 22 kg/d DMI in the 
control diet. Treatments were premixed with ground corn and offered as a top-dress at a rate of 
200 g/cow daily for 35 d. Treatments were control, Cr propionate (CrPr; 8 mg/d Cr in the form of 
20 g/d KemTRACE Chromium Propionate 0.04%, Kemin Industries, Inc., Des Moines, IA), 
rumen-protected lysine and methionine (RPLM; 10 g/d lysine and 5 g/d methionine, intestinally 
available), or both (CrPr+RPLM). The RPLM supplement was composed of 48.8 g/d of 
LysiPEARL and 15.3 g/d of MetiPEARL (Kemin Industries, Inc.), and was predicted to provide 
Lys and Met supplies of 6.77% and 2.23% of MP, respectively. Cows were milked 3 times daily 
(0300, 1100, and 1900 h) and fed once daily (1600 h) for ad libitum intake, targeting 10% daily 
refusals. 
 
 Sample and Data Collection  
Feed offered and feed refused were measured for each cow daily to determine DMI. Milk 
yield was recorded for each cow daily. Body weights and BCS (Wildman et al., 1982) were 
measured on d 1 and 35. Milk samples were collected 3 d per week for milk composition analysis. 
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Samples of feed ingredients were collected weekly and frozen for analysis. On d 19 to 21 and 33 
to 35, samples of TMR and feed refusals were collected daily and fecal samples were collected at 
9 h intervals, representing every 3 h of a 24-h period. 
 
 Sample Analysis  
Samples of diet ingredients, TMR, and feed refusals were dried in a 55°C forced air oven 
for 48 h, composited by collection period (d 21 vs. 35), ground through a 1-mm screen (Wiley 
mill, Arthur H. Thomas, Swedesboro, NJ), and analyzed for DM, OM, CP, NDF, and ether extract 
(EE). The DM content was determined by drying at 105°C in a forced-air oven for 16 h. Ash 
concentration was determined after 4 h of oxidation at 500°C in a muffle furnace. Nitrogen content 
was determined by oxidation and detection of N2 (Leco Analyzer, Leco Corp., St. Joseph, MI). 
Concentration of NDF was determined using an Ankom Fiber Analyzer (Ankom Technology, 
Fairport, NY) including amylase and sodium sulfite (Van Soest et al., 1991). Crude fat was 
determined by ether extraction (AOAC, 2000; method 920.9). 
 Milk samples were analyzed for concentration of fat, true protein, lactose (B-2000 Infrared 
Analyzer; Bentley Instruments, Chaska, MN), MUN (MUN spectrophotometer, Bentley 
Instruments), and somatic cells (SCC 500, Bentley Instruments) by Heart of America DHIA 
(Manhattan, KS). 
  
 Energy Balance 
The concentration of acid detergent insoluble ash (ADIA) was determined (Van Soest et 
al., 1991) in dried samples of feed ingredients, refusals, and feces. This parameter was used as an 
endogenous indigestible marker to estimate fecal output (Cochran et al., 1986). The gross energy 
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(GE) content of feed, top-dressed treatments, refusals, and dried fecal samples were determined 
by bomb calorimetry. Intake of GE was calculated as GE in feed offered (calculated from analysis 
of feed ingredients) minus GE in refusals; fecal GE was subtracted to determine DE intake. After 
calculating DE concentration of the diets by cow (DE intake / DMI), ME and NEL concentrations 
were calculated using the following formulas (National Research Council, 2001): ME (Mcal/kg 
DM) = [1.01 × (DE, Mcal/kg) - .045] + 0.0046 × (EE, % - 3), and NEL (Mcal/kg) = 0.703 × ME 
(Mcal/kg) – 0.19 + [(0.097 × ME, Mcal/kg + 0.19)/97] × (EE, % - 3). Intakes of ME and NEL were 
then determined by multiplying these concentrations by DMI. Milk energy output (Mcal) was 
calculated as 9.29 × kg of milk fat + 5.47 × kg of milk protein + 3.095 × kg of milk lactose, and 
maintenance energy requirements (Mcal/d) estimated as 0.08 × kg of BW0.75 (National Research 
Council, 2001). To determine NEL balance, milk and maintenance energy were subtracted from 
NEL intake. 
  
 Statistical Analysis  
One cow on CrPr+RPLM developed severe mastitis on d 20 of treatment and was 
subsequently removed from the study. No data were collected or analyzed for this cow. Milk and 
DMI data were averaged by week prior to analysis. Data were analyzed using the Mixed Procedure 
of SAS (version 9.2; SAS Institute Inc., Cary, NC) to assess the fixed effects of parity (primiparous 
vs. multiparous), time, CrPr, RPLM, and 2-, 3-, and 4-way interactions, and the random effect of 
block. With the exception of CrPr × RPLM, interactions were removed from models when P > 
0.30. Repeated measures over time within cow were modeled with an autoregressive (AR[1]) 
covariance structure. Denominator degrees of freedom were estimated using the Kenward-Rogers 
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method. Significance was declared at P ≤ 0.05 and tendencies at 0.05 < P < 0.10. Treatment means 
were separated with pair-wise t-tests when interactions were significant. 
 
 Results and Discussion 
Dry matter intake was significantly increased by CrPr (P < 0.05), but was not significantly 
affected by RPLM when fed for 5 wk near peak lactation (Table 2). Although neither RPLM nor 
CrPr significantly altered yields of milk or milk components, CrPr tended to increase ECM (P = 
0.09) by 6% (Table 4.2). In addition, there was evidence of parity × CrPr interactions for both DMI 
(P = 0.06) and milk protein yield (P = 0.04), in both cases indicating positive responses to CrPr in 
primiparous cows but not in multiparous cows (Figures 4.1A and 4.1B). 
 Several lines of evidence indicate that Cr supplementation during the periparturient period 
improves DMI and milk production (Hayirli et al., 2001; McNamara and Valdez, 2005). Hayirli et 
al. (2001) reported that supplementation of 0, 3.9, 8.3, and 16.5 mg Cr/d from Cr-methionine 
resulted in a linear increase in prepartum DMI.  Besong et al. (1996) observed increased milk yield 
in the first 8 wk of lactation in cows supplemented with 0.8 mg Cr/kg DMI as Cr-picolinate.  Smith 
et al. (2005) found that supplementation of 0.03 or 0.06 mg of Cr/kg BW0.75 increased DMI and 
milk yield in early lactation. In heat stress conditions, Cr supplementation from 3 wk prepartum 
through 12 wk postpartum improved postpartum DMI and increased milk yield by 6.7%, 12.3%, 
and 16.5% at 4, 8, and 12 wk postpartum, respectively (Soltan, 2010). In these studies, feed 
efficiency was essentially unaffected, because the increases in milk yield and DMI in response to 
Cr supplementation paralleled each other.  
 The interaction of RPLM and CrPr affected milk protein content (P = 0.04, Table 4.2). 
Somewhat counter-intuitively, in the absence of CrPr, RPLM decreased milk protein content (P < 
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0.01), but no effect of RPLM was detected in the presence of CrPr (P = 0.77). Rumen-protected 
lysine and methionine also decreased the efficiency of N utilization for milk protein (P = 0.05). 
Rumen-protected methionine (RPM) supplementation has been reported to increase milk protein 
content in many studies  (Doreau and Chilliard, 1997; Leonardi et al., 2003; Pacheco et al., 2006), 
but not in others  (Papas et al., 1984; Davidson et al., 2008). Fewer studies (Armentano et al., 1997; 
Rulquin and Delaby, 1997) observed increased milk protein yield. Dietary supplementation of 
methionine or both methionine and lysine can significantly increase N utilization efficiency (Wang 
et al., 2010), but Noftsger and St-Pierre (2003) did not observe an improvement in N efficiency 
when they evaluated supplemental methionine in a digestibility trial. Likewise, varying results 
have been reported for milk and milk fat yields. In light of the inconsistent data, a meta-analysis 
(Patton, 2010) was conducted to investigate the effect of RPM supplementation on production. 
The results indicated that RPM addition to diets increased milk protein, both as percentage (0.07%) 
and yield (27 g/d), and slightly increased milk yield. However, DMI and milk fat percentage were 
slightly decreased. Therefore, although there is a lack of research on the simultaneous addition of 
both RPL and RPM on milk components, the decreased milk protein content by RPLM in our 
study was unexpected.  
There was a CrPr × week interaction (P = 0.04) for lactose content, reflecting significantly 
greater lactose content (4.99 vs. 4.86 ± 0.036%) in response to CrPr during wk 1, with no 
differences observed from wk 2 on. Previous work has demonstrated enhanced glucose utilization 
in cattle supplemented with Cr (Sumner et al., 2007), consistent with the view that Cr acts primarily 
as an insulin sensitizing agent. However, we are not aware of other studies in lactating cows 
reporting increased milk lactose content in response to supplemental Cr, so it is somewhat unclear 
what caused this response or why it was transient. 
  
111 
 Intake of GE and DE and digestibility of GE and DM were similar across treatments (P > 
0.10), and no treatment effects were detected for NEL balance, BW change, or BCS change (Table 
4.3). The negative values for BW and BCS changes, which suggested that cows were in a catabolic 
state, appear to conflict with the positive calculated NEL balances. However, BW and BCS change 
data covered the entire 35-d experiment, whereas NEL balance was only determined on d 21 and 
35. It is likely that many cows (mean 38 DIM at the start and 73 DIM at the end of the study) 
moved from a negative energy balance to a positive energy balance during the course of the study. 
Nevertheless, the accuracy of calculated NEL balance may have been limited due to biased 
estimations of fecal output with the ADIA marker. Dietary ADIA concentrations were relatively 
low in this experiment, potentially increasing variability in ADIA intake estimates, which could 
result in underestimated fecal mass and overestimated supply of energy. The magnitude of this 
potential bias was estimated by comparing NEL values calculated from measured energy 
digestibility vs. model-derived NEL values based on ingredient characterization alone (Table 4.1). 
This comparison suggested that marker-based digestibility analysis may have overestimated ME 
supply by approximately 17%. Regardless, relative treatment differences were valid because of 
the common basal diet, and the lack of an effect of Cr on energy balance is consistent with previous 
findings in early lactation (Smith et al., 2005; Sadri et al., 2009). 
Plasma AA profiles are presented in Table 4.4. The proportion of lysine significantly 
increased (P = 0.05) and that of methionine tended to increase (P = 0.07) in response to RPLM. 
On the other hand, the proportion of threonine was significantly decreased by RPLM (P < 0.01). 
A tendency for a CrPr × RPLM interaction (P = 0.06) was observed for tryptophan, reflecting a 
decreased proportion of tryptophan by CrPr in the presence of RPLM (P = 0.03), but not in the 
absence of RPLM (P = 0.64). The plasma lysine and methionine responses to RPLM were less 
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than might have been expected, given the lack of increased milk protein yield. We observed 
approximately a 10% increase in lysine and 6% increase in methionine as a proportion of AA in 
response to estimated supplementation of 10 and 5 g/d, respectively. Similar supplementation rates 
have increased plasma concentrations by more than 30% (Rogers et al., 1987), though without any 
change in milk protein yield in mid-lactation cows producing approximately 30 kg milk/d. 
Compared to our work, the cows evaluated by Rogers et al. (1987) may have been more responsive 
to AA supplementation (in terms of plasma concentrations) because of lower microbial supply of 
AA and because of stable AA demands for protein synthesis. Few studies have evaluated responses 
to supplemental AA in cows during the transition from the catabolic state in early lactation to an 
anabolic state. Previous work has demonstrated that muscle repletion occurs during this stage of 
lactation and has suggested that increases in intestinally available methionine may enhance this 
process (Phillips et al., 2003). Whether or not such a response interferes with potential milk protein 
responses to bypass essential AA is unknown and may be a fruitful area of investigation, especially 
considering the complex interactions of AA supply and insulin signaling to influence both muscle 
deposition and milk protein synthesis (Bequette et al., 2001). 
 
 Conclusions 
The supplementation of CrPr increased DMI and tended to increase ECM yield of peak-
lactation cows when fed for a 5-wk period, and DMI as well as milk protein yield was particularly 
enhanced in primiparous cows. The inclusion of RPLM increased lysine and tended to increase 
methionine as a proportion of plasma AA, but decreased the efficiency of N utilization for milk 
protein. These findings indicate that responses to dietary Cr in the dairy cow are not limited to 
early lactation.  
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 Tables and Figures 
Table 4.1. Ingredient and nutritional composition of the basal diet 
Ingredient % of DM  
Corn silage 31.5  
Alfalfa hay 23.4  
Wet corn gluten feed1 6.8  
Ground corn 23.1  
Whole cottonseed 4.6  
Mechanically extracted soybean meal2 2.1  
Solvent extracted soybean meal 5.1  
Ca salts of long-chain fatty acids3 0.8  
Micronutrient premix4 2.6  
   
Nutrient   
DM, % as-fed 57.9  
OM 91.3  
CP 16.7  
NDF 31.7  
ADF 20.1  
fNDF5 22.1  
NFC 39.8  
Ether extract 3.1  
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GE, Mcal/kg 4.11  
DE6, Mcal/kg 3.34  
ME7, Mcal/kg 2.92  
NEL8, Mcal/kg 1.87  
Model-predicted ME9, Mcal/kg 2.50  
 
1SweetBran, Cargill Inc., Blair, NE 
2Soy Best, Grain States Soya, West Point, NE 
3Megalac-R, Church & Dwight Co, Princeton, NJ  
4Premix consist of 45.1% limestone, 32.2% of sodium 
bicarbonate, 6.4% magnesium oxide, 5.2% sodium chloride, 
5.2% vitamin E premix (44 IU/g), 0.45% vitamin A premix (30 
IU/g), 0.19% vitamin D premix (30 IU/g), 2.1% 4-Plex (Zinpro 
Corp., Eden Prairie, MN; contains 2.58% Zn, 1.48% Mn, 0.90% 
Cu, 0.18% Co, 8.21% Met, and 3.80% Lys), 0.96% selenium 
premix (600 ppm Se), 0.45% Zinpro 100 (Zinpro Corp.; contains 
10% Zn and 20% Met), 0.03% ethylenediamine dihydriodide 
premix (3.65% I), 0.88% Kallsil (Kemin Industries), and 0.88% 
Myco CURB (Kemin Industries). 
5forage NDF 
6DE = (Gross energy intake – gross energy in feces)/DMI. 
7ME = [1.01 × (DE, Mcal/kg) - 0.045] + 0.0046 × (EE, % -3). 
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8NEL = 0.703 × ME (Mcal/kg) – 0.19 + [(0.097 × ME, Mcal/kg 
+ 0.19)/97] × [EE, % -3].  
9ME predicted by CNCPS 6.1 (NDS version 3, Ruminant 
Management & Nutrition, Reggio Emilia, Italy). 
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Table 4.2 . Chromium propionate (CrPr) and rumen-protected lysine and methionine (RPLM) effects on intake, productivity, 
and milk composition of lactating dairy cows 
 Control RPLM  P-value 
 Item Control CrPr Control CrPr SEM CrPr RPLM Interaction 
DMI, kg/d 19.9 22.2 21.7 22.3 1.10 < 0.05 0.18 0.23 
Milk yield, kg/d 40.5 43.7 42.4 43.3 1.44 0.14 0.61 0.39 
Milk fat, % 4.20 4.13 3.95 3.97 0.15 0.88 0.19 0.74 
Milk protein, % 2.75 2.67 2.62 2.68 0.04 0.66 0.09 0.04 
Milk lactose, % 4.90 4.99 4.89 4.90 0.04 0.26 0.24 0.37 
MUN, mg/dL  13.2 14.0 13.8 13.1 0.56 0.89 0.70 0.09 
SCC linear score 1.59 1.10 1.58 1.65 0.50 0.66 0.56 0.56 
Fat yield, kg/d 1.68 1.81 1.66 1.70 0.07 0.27 0.37 0.58 
Protein yield, kg/d 1.12 1.16 1.12 1.17 0.03 0.22 0.93 0.86 
Lactose yield, kg/d 2.01 2.17 2.09 2.15 0.07 0.15 0.74 0.54 
Milk N efficiency2, %  30.2 27.6 27.0 27.1 1.17 0.19  < 0.05 0.15  
ECM1, kg/d 43.1 46.3 43.1 44.9 1.47 0.09 0.62 0.65 
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ECM/DMI 2.18 2.08 2.02 2.02 0.08 0.53 0.16 0.56 
1ECM = (0.327 × milk yield) + (12.95 × fat yield) + (7.65 × protein yield); (Dairy Record Management Systems, 2013) 
2 N efficiency = milk protein N / N intake. 
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Table 4.3. Chromium propionate (CrPr) and rumen-protected lysine and methionine (RPLM) effects on energy balance of 
lactating dairy cows 
 
 Control RPLM  P-value  
Item  Control CrPr Control CrPr SEM CrPr RPLM Interaction  
GE intake, Mcal/d 92.8 100.8 98.1 101.1 4.18 0.10 0.42 0.46  
DE intake, Mcal/d 76.1 82.5 80.8 81.2 3.31 0.20 0.52 0.25  
GE digested, % 81.4 82.0 82.2 81.1 1.43 0.86 0.97 0.51  
DM digestibility, % 81.0 81.7 82.6 80.9 1.35 0.67 0.72 0.33  
NEL balance, Mcal/d 3.3 6.3 7.7 6.7 1.89 0.56 0.15 0.25  
BW change, kg / 28 d -14.6 -9.9 -13.7 -7.9 4.15 0.21 0.74 0.89  
BCS change, / 28 d -0.31 -0.32 -0.33 -0.27 0.09 0.06 0.86 0.32  
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Table 4.4. Chromium propionate (CrPr) and rumen-protected lysine and methionine (RPLM) effects on plasma amino acids on 
lactating dairy cows 
 
Amino Acid  Control RPLM  P-value 
(Molar % of total AA) Control CrPr Control CrPr SEM CrPr RPLM Interaction 
Glycine 15.57 15.07 14.98 13.92 1.10 0.48 0.42 0.80 
Valine 12.19 12.19 11.90 11.07 0.65 0.47 0.28 0.53 
Alanine 10.88 11.84 11.72 11.53 0.43 0.37 0.52 0.18 
Glutamine 8.70 7.97 8.95 9.44 0.58 0.81 0.09 0.22 
Leucine 8.20 8.08 8.11 7.89 0.45 0.66 0.71 0.91 
Isoleucine 6.82 6.63 6.77 6.71 0.40 0.72 0.96 0.86 
Threonine 4.52 4.72 4.17 3.97 0.24 0.99 0.02 0.25 
Citruline 4.40 4.65 4.08 4.18 0.34 0.32 0.23 0.81 
Serine 3.95 3.96 3.99 3.81 0.17 0.58 0.73 0.55 
Arginine 3.61 4.07 4.01 3.94 0.21 0.30 0.45 0.16 
Lysine 3.34 3.37 3.80 3.59 0.17 0.55 0.05 0.47 
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Glutamate 3.02 2.91 2.78 2.85 0.28 0.91 0.47 0.67 
Tyrosine 2.14 2.15 2.30 2.23 0.10 0.75 0.22 0.65 
Histidine 2.10 2.09 1.89 2.05 0.07 0.28 0.09 0.25 
Asparagine 2.06 1.85 2.20 2.22 0.24 0.63 0.18 0.55 
Phenylalanine 1.97 1.96 2.13 2.03 0.08 0.43 0.11 0.52 
Taurine 1.75 1.90 1.58 1.80 0.17 0.27 0.41 0.83 
Ornithine 1.73 1.68 1.77 1.73 0.10 0.56 0.64 0.97 
Tryptophan 1.63 1.68 1.73 1.53 0.07 0.18 0.69 0.06 
Methionine 0.95 0.99 1.06 1.01 0.04 0.93 0.07 0.12 
Aspartate 0.32 0.38 0.33 0.34 0.02 0.13 0.51 0.28 
Total amino acids, mM 2.47 2.39 2.14 2.39 0.10 0.39 0.11 0.11 
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Figure 4.1. Interactions of chromium propionate (CrPr) and parity for milk protein yield 
(A) and dry matter intake (B). Supplements were fed for 35 d near peak lactation, and DMI 
and milk production responses were analyzed by week throughout the study. Values are 
LSM ± SEM, n = 10 to 13. 
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Appendix A - Supplemental Table and Figure 
Supplemental Table 1. In vitro long chain fatty acid concentrations with different sources 
and concentrations of cobalt in Experiment 2 
 
  CoCarb CoGH   
g/100g of 
FA 0 0.33 1 3 9 0.33 1 3 9 
SEM Contrast1 
C6:0 3.92 2.76 3.36 5.39 5.45 3.14 4.09 2.89 4.17 0.67 bCE 
C8:0 0.06 0.04 0.05 0.07 0.08 0.04 0.05 0.04 0.06 0.01 bCE 
C10:0 0.52 0.46 0.51 0.81 1.21 0.48 0.98 0.58 0.95 0.15 ACe 
C11:0 0.18 0.14 0.17 0.24 0.26 0.17 0.21 0.14 0.19 0.03 bCE 
C12:0 0.60 0.51 0.57 0.76 0.78 0.54 0.66 0.51 0.65 0.07 bCE 
C14:0 1.83 1.57 1.74 2.22 2.23 1.67 1.95 1.59 1.91 0.16 bCE 
C15:0 1.72 1.50 1.62 2.15 2.22 1.55 1.86 1.50 1.80 0.17 BCE 
C16:0 21.78 21.28 21.64 22.60 22.18 21.48 21.99 21.24 21.47 0.45 bE 
C16:1 0.40 0.38 0.41 0.47 0.46 0.39 0.41 0.39 0.43 0.02 C 
C17:0 0.88 0.74 0.81 1.10 1.17 0.78 0.97 0.73 0.89 0.10 BCE 
C18:0 25.42 23.69 24.34 26.74 27.50 23.09 24.17 23.23 24.04 0.82 BCE 
C18:1n11c 1.89 1.74 1.84 2.10 2.17 1.82 2.02 1.79 2.04 0.09 CE 
C18:1n11t 18.46 20.27 19.28 14.29 13.44 20.05 16.57 20.60 17.71 1.35 BCE 
C18:1n9c 7.75 8.98 8.20 6.77 6.55 8.62 8.26 8.59 7.69 0.53 BCE 
C18:1n9t 2.36 2.06 2.24 2.78 2.89 2.11 2.55 2.03 2.40 0.22 bCE 
C18:3n3 0.73 0.82 0.76 0.63 0.64 0.79 0.68 0.84 0.85 0.08 bC 
C18:2n6c 7.33 8.57 7.86 6.30 5.88 8.71 7.09 8.81 7.77 0.91 BCE 
C18:2n6t 0.14 0.11 0.13 0.19 0.19 0.13 0.17 0.11 0.16 0.02 CE 
C20:0 0.53 0.56 0.54 0.50 0.51 0.54 0.50 0.57 0.54 0.02 E 
C20:1 0.15 0.14 0.13 0.13 0.12 0.14 0.13 0.15 0.15 0.01 Abe 
C20:2 0.03 0.04 0.04 0.02 0.01 0.03 0.03 0.03 0.02 0.01 Ce 
C21:0 0.07 0.07 0.07 0.07 0.07 0.07 0.08 0.06 0.07 0.004  
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C22:0 0.42 0.45 0.44 0.37 0.39 0.44 0.39 0.46 0.44 0.03 E 
C22:5n3 1.06 0.82 0.93 1.33 1.43 0.87 1.18 0.79 1.10 0.15 bCE 
C23:0 0.15 0.14 0.14 0.13 0.12 0.14 0.14 0.14 0.15 0.01 BE 
C24:0 0.49 0.53 0.51 0.46 0.48 0.52 0.46 0.54 0.53 0.06 dE 
C24:1 0.12 0.10 0.11 0.17 0.21 0.10 0.15 0.08 0.14 0.02 BCE 
CLA10t12c 0.35 0.38 0.37 0.32 0.31 0.37 0.35 0.38 0.37 0.02 bcE 
CLA9c11c 0.05 0.06 0.05 0.03 0.03 0.06 0.04 0.06 0.07 0.01 BE 
CLA9c11t 0.56 0.71 0.62 0.47 0.55 0.63 0.52 0.73 0.73 0.07 dE 
CLA9t11t 0.50 0.60 0.53 0.44 0.43 0.56 0.51 0.47 0.50 0.04 C 
1A = No supplemental Co vs. all other treatments; 
 B = source effect; 
 C = linear dose; 
 D = quadratic dose; 
 E = linear dose × source; 
 F = quadratic dose × source; 
 Upper case = P < 0.05; lower case = P < 0.10. 
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1A = No supplemental Co vs. all other treatments; 
 B = source effect; 
 C = linear dose; 
 D = quadratic dose; 
 E = linear dose × source; 
 F = quadratic dose × source; 
 Upper case = P < 0.05; lower case = P < 0.10.  
 
Supplemental Figure 1. In vitro trans-10, cis-12 CLA and cis-9, trans-11 CLA concentrations 
with different sources and concentrations of cobalt. The X-axis represent the concentration 
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of Co expressed in ppm, and the Y-axis indicate the grams of fatty acid in 100 g of total fat.  
1A = No supplemental Co vs. all other treatments; B = source effect; C = linear dose; D = 
quadratic dose; E = linear dose × source; F = quadratic dose × source; Upper case = P < 0.05; 
lower case = P < 0.10. 
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